This Non-Disclosure Agreement (this “Agreement”) is entered into as of today’s date by and between:
Cullari & Wardell LLC, a Wyoming limited liability company doing business as LUKE, with its principal place of business at 1309 Coffeen Avenue STE 1200, Sheridan, Wyoming 82801 (the “Disclosing Party” or “Company”);
and
The undersigned individual or entity identified below (the “Receiving Party”).
WHEREAS, the Disclosing Party has developed and is developing a multi-tenant SaaS platform known as LUKE (the “Platform”), including associated business plans, financial projections, technical architecture, product roadmaps, pricing models, customer data, marketing strategies, proprietary algorithms, source code, AI agent technology, advertising intelligence systems (including the Artemis Targeting platform), and related intellectual property; and
WHEREAS, the Disclosing Party wishes to disclose certain confidential and proprietary information to the Receiving Party for the limited purpose of evaluating a potential business relationship, investment opportunity, partnership, advisory engagement, or other transaction (the “Purpose”); and
WHEREAS, the Receiving Party acknowledges that such information is proprietary and confidential and agrees to protect it in accordance with the terms of this Agreement;
1.1 “Confidential Information” means any and all non-public information disclosed by the Disclosing Party to the Receiving Party, whether disclosed orally, in writing, electronically, visually, or by any other means, and whether or not marked as “confidential,” including but not limited to:
(a) Business Information: business plans, financial projections, revenue models, pricing strategies, unit economics, customer acquisition costs, churn rates, lifetime value calculations, market analyses, competitive assessments, go-to-market strategies, partnership strategies, and investor materials;
(b) Technical Information: software architecture, source code, database schemas, API designs, encryption methodologies, security protocols, AI model configurations, multi-model routing logic, deployment procedures, infrastructure specifications, and testing frameworks;
(c) Product Information: product roadmaps, feature specifications, user interface designs, Rx verification gate logic, audit trail architecture, tenant isolation mechanisms, AI agent conversational flows, voice agent configurations, POS integration protocols, and patient engagement system designs;
(d) Customer and Market Data: customer lists, tenant information, prospect lists, lead scoring algorithms, conversion metrics, patient data models (excluding any individually identifiable patient health information), and commercial performance data;
(e) Related Platform Information: information relating to the Artemis Targeting platform, CW/AD AI Agent platform, and any other Cullari & Wardell technology, product, or service disclosed in connection with the Purpose; and
(f) Any Other Information: any other information that a reasonable person would understand to be confidential given the nature of the information and the circumstances of disclosure.
1.2 Confidential Information does not include information that: (a) is or becomes publicly available through no fault of the Receiving Party; (b) was known to the Receiving Party prior to disclosure, as demonstrated by written records predating such disclosure; (c) is independently developed by the Receiving Party without use of or reference to the Confidential Information, as demonstrated by written records; or (d) is lawfully received from a third party without restriction on disclosure and without breach of any obligation of confidentiality.
2.1 The Receiving Party shall: (a) hold all Confidential Information in strict confidence; (b) not disclose Confidential Information to any third party without the prior written consent of the Disclosing Party; (c) use the Confidential Information solely for the Purpose and for no other purpose whatsoever; (d) protect the Confidential Information using at least the same degree of care it uses to protect its own confidential information, but in no event less than a reasonable degree of care; and (e) limit internal access to Confidential Information to those of its employees, officers, directors, advisors, attorneys, accountants, and consultants who have a need to know for the Purpose and who are bound by confidentiality obligations no less restrictive than those contained herein.
2.2 The Receiving Party shall be responsible for any breach of this Agreement by any person to whom it discloses Confidential Information in accordance with Section 2.1(e).
2.3 The Receiving Party shall not reverse engineer, disassemble, decompile, or otherwise attempt to derive the source code, algorithms, data structures, or underlying ideas or concepts of any software, technology, or system described in or constituting the Confidential Information.
2.4 The Receiving Party shall not use the Confidential Information to develop, design, create, market, or sell any product, service, or platform that is competitive with or substantially similar to the Platform or any related Cullari & Wardell technology.
3.1 During the term of this Agreement and for a period of two (2) years following the expiration or termination of this Agreement, the Receiving Party shall not, directly or indirectly: (a) solicit, recruit, or hire any employee, contractor, or consultant of the Disclosing Party; (b) solicit or attempt to solicit business from any customer, client, tenant, or prospective customer of the Disclosing Party that was identified through or in connection with the Confidential Information; or (c) circumvent, avoid, bypass, or attempt to circumvent the Disclosing Party in order to directly contact, negotiate with, or enter into any business arrangement with any party introduced to or identified by the Receiving Party through the Confidential Information.
4.1 Nothing in this Agreement grants the Receiving Party any license, right, title, or interest in or to any Confidential Information, intellectual property, patent, copyright, trademark, trade secret, or other proprietary right of the Disclosing Party. All Confidential Information remains the sole and exclusive property of the Disclosing Party.
4.2 Nothing in this Agreement obligates the Disclosing Party to disclose any particular Confidential Information, to enter into any further agreement, or to proceed with any transaction or business relationship.
5.1 If the Receiving Party is compelled by law, regulation, legal process, or governmental order to disclose any Confidential Information, the Receiving Party shall: (a) provide the Disclosing Party with prompt written notice of such requirement prior to disclosure (to the extent legally permitted) so that the Disclosing Party may seek a protective order or other appropriate remedy; (b) cooperate with the Disclosing Party in seeking such protective order or remedy at the Disclosing Party’s expense; and (c) disclose only that portion of the Confidential Information that is legally required to be disclosed.
6.1 Upon the written request of the Disclosing Party or upon termination of this Agreement, the Receiving Party shall promptly: (a) return to the Disclosing Party all documents, files, and materials containing or based upon Confidential Information; or (b) at the Disclosing Party’s election, destroy all such documents, files, and materials and provide the Disclosing Party with a written certification of destruction.
6.2 The Receiving Party may retain one (1) archival copy of the Confidential Information solely for legal compliance purposes, provided that such copy remains subject to the confidentiality obligations of this Agreement.
7.1 This Agreement shall remain in effect for a period of five (5) years from the Effective Date, unless earlier terminated by either Party upon thirty (30) days’ written notice.
7.2 The confidentiality obligations shall survive the expiration or termination of this Agreement for a period of five (5) years from the date of disclosure. With respect to trade secrets, the confidentiality obligations shall continue for so long as such information qualifies as a trade secret under applicable law.
8.1 The Receiving Party acknowledges that any breach or threatened breach of this Agreement may cause irreparable harm to the Disclosing Party for which monetary damages would be an inadequate remedy. The Disclosing Party shall be entitled to seek equitable relief, including injunction and specific performance, without the requirement of posting a bond.
8.2 In the event of a breach, the Receiving Party shall be liable for all damages suffered by the Disclosing Party, including direct damages, consequential damages, lost profits, and reputational harm.
8.3 The prevailing Party in any legal proceeding arising out of this Agreement shall be entitled to recover its reasonable attorneys’ fees and litigation expenses.
9.1 Each Party represents and warrants that: (a) it has the full legal authority and capacity to enter into this Agreement; (b) the execution and performance of this Agreement does not violate any other agreement to which it is a party; and (c) this Agreement constitutes a valid and binding obligation enforceable in accordance with its terms.
10.1 This Agreement shall be governed by and construed in accordance with the laws of the State of Wyoming, without regard to its conflict of laws principles.
10.2 Any dispute arising out of this Agreement shall be subject to the exclusive jurisdiction of the state and federal courts located in the State of Wyoming.
11.1 Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof.
11.2 Amendments. This Agreement may not be amended except by a written instrument signed by both Parties.
11.3 Assignment. The Receiving Party may not assign this Agreement without the prior written consent of the Disclosing Party.
11.4 Waiver. No waiver of any provision shall be effective unless in writing and signed by the waiving Party.
11.5 Severability. If any provision is held invalid, the remaining provisions shall continue in full force and effect.
11.6 No Partnership or Agency. Nothing in this Agreement shall be construed to create a partnership, joint venture, agency, or employment relationship between the Parties.
DISCLOSING PARTY:
Cullari & Wardell LLC, a Wyoming LLC d/b/a LUKE
LUKE is a multi-tenant SaaS platform that unifies clinical workflows, prescription-gated e-commerce, fitness and wellness management, CRM, AI-powered patient engagement, and HIPAA compliance into a single system purpose-built for telehealth practices, hybrid clinical-fitness operations, and wellness businesses selling products and services online.
The platform addresses a $44+ billion addressable market spanning hormone replacement therapy, peptide therapeutics, GLP-1 weight management, medical aesthetics, and gym/fitness management software. Today, practices in these verticals stitch together five to seven disconnected tools to manage patient records, verify prescriptions, process orders, schedule classes, track leads, and maintain compliance. Each vendor requires a separate BAA, a separate login, and a separate prayer that patient data stays consistent across systems.
LUKE eliminates this fragmentation. One platform, one vendor, one Business Associate Agreement. Purpose-built HIPAA compliance infrastructure — per-tenant encryption, tamper-evident audit trails, and automated breach detection — is enforced architecturally, not bolted on (see Section 5).
LUKE is the second production SaaS platform built and operated by Cullari & Wardell, which also runs the Artemis Targeting platform and the CW/AD AI Agent platform. Artemis provides a built-in distribution channel: medical practices already using Artemis for patient acquisition are warm leads for LUKE, reducing customer acquisition costs by 60–70% and creating a closed-loop flywheel between advertising and commerce. The AI Agent platform — with nearly 100 live deployments — provides the proven conversational AI architecture that powers LUKE’s patient engagement layer.
| Metric | Year 1 | Year 2 | Year 3 | Year 5 |
|---|---|---|---|---|
| Active Tenants | 5 | 25 | 80 | 275 |
| Annual Recurring Revenue | $110K | $565K | $1.8M | $6.6M |
| Transaction Fee Revenue | $27K | $320K | $1.4M | $5.8M |
| Total Revenue | $155K | $970K | $3.5M | $12.9M |
Revenue model combines platform subscriptions ($799–$3,499/month), usage-based AI and per-provider seat expansion, one-time onboarding fees ($2,500–$10,000), and a 1.5% transaction fee on e-commerce order volume that scales with tenant success.
Legal Entity: Cullari & Wardell (DBA LUKE)
Website: luke.care
Founded: 2021 (Cullari & Wardell); 2025 (LUKE platform development)
Incorporated: Wyoming
Headquarters: New Jersey
Structure: Family-owned LLC
To give every telehealth practice selling prescription products the infrastructure to operate as if they had a $300,000 custom platform — deployed in two weeks, for $1,499 a month.
LUKE will become the operating system for prescription commerce: the platform where clinical data, regulatory compliance, e-commerce, and patient relationships live in one connected, auditable system. We believe the practices that will win in telehealth are the ones that stop stitching together disconnected tools and start running on purpose-built infrastructure.
Cullari & Wardell was founded in 2021 as a Wyoming LLC headquartered in New Jersey, operating as an advertising and technology company. The company has evolved into a full-service advertising technology firm operating multiple brands, including Artemis Targeting, CW/AD Agency, and now LUKE. The company has deep experience across healthcare, biotech, financial services, and direct-to-consumer brands.
Artemis Targeting is a production AI-powered geotargeting platform with 4,260+ targeting segments and sub-200ms API latency. It runs on the same infrastructure stack as LUKE — Python 3.11/FastAPI, PostgreSQL, Redis, Hetzner Cloud (Docker Compose), and OpenTelemetry — sharing engineering patterns, deployment pipelines, and observability standards. LUKE is the second product on a proven operational foundation, not a first attempt at building software.
LUKE emerged from a recurring pattern across Cullari & Wardell’s healthcare and DTC clients: practices needed a single platform unifying clinical workflows, Rx-gated checkout, CRM, and HIPAA compliance — and no existing solution addressed all these domains. LUKE was built to fill that gap, designed from day one as multi-tenant infrastructure. The platform has since expanded to six domains with the addition of AI engagement and fitness & wellness capabilities.
LUKE operates at the intersection of four converging healthcare verticals, each independently experiencing significant growth:
| Market | 2024 Value | CAGR | 2033 Projection |
|---|---|---|---|
| Hormone Replacement Therapy | $23.6B | 5.8% | $39.4B |
| Testosterone Replacement | $2.1B | 8.9% | $3.2B |
| Peptide Therapeutics | $46–117B | 7–11% | $65–260B |
| Medical Spa Services | $21.2B | 15.8% | $78.2B |
| DTC Telehealth (U.S.) | $7.5B | 12.2% | $16.8B |
| Gym Management Software | $1.78B | 14–18% | $5.5–7.5B |
Sources: Grand View Research, Mordor Intelligence, SkyQuest, IMARC Group, Precedence Research, NovaOne Advisor, Fortune Business Insights. Ranges reflect differing scope definitions across research firms.
LUKE’s SAM is the subset of these markets where practices operate a telehealth-plus-commerce model and/or a hybrid clinical-fitness model: they consult patients virtually, verify prescriptions, fulfill products through an online storefront, and—increasingly—integrate fitness and wellness programming into their clinical offerings. This includes TRT clinics, peptide therapy providers, GLP-1 weight management practices, hormone optimization clinics, med spas with Rx skincare lines, and hybrid clinical-fitness operations combining medical oversight with membership-based wellness programs.
We estimate approximately 12,000–18,000 practices in the United States currently operate or are actively building this model, based on the following indicators: there are 11,500+ medical spas operating in the U.S. (AmSpa, 2025), with a meaningful subset selling Rx products online; the TRT/hormone clinic market includes both independent clinics and chains like Low T Center scaling nationally; telehealth peptide/GLP-1 brands are launching at an accelerating rate, with top DTC peptide brands doing $5M–$25M+ annually; and the growing trend of medically-supervised fitness programs—sports medicine clinics with performance training, concierge practices with fitness components, and functional medicine clinics offering movement therapy—adds an estimated 3,000–5,000 hybrid practices to the addressable base.
At LUKE’s average revenue per tenant of approximately $18,000/year (Professional tier plus transaction fees), capturing 5% of this expanded market — roughly 700–900 tenants — represents $12.6–$16.2M in annual recurring revenue.
The DEA extended COVID-era telemedicine prescribing flexibilities through December 31, 2026, allowing practitioners to remotely prescribe Schedule II–V controlled substances (including testosterone, Schedule III) via telehealth without requiring a prior in-person visit. Four bills are pending in Congress to make these flexibilities permanent. This regulatory posture directly enables the telehealth hormone therapy model that LUKE supports.
Simultaneously, the FDA is increasing enforcement against non-compliant DTC telehealth operators. In September 2025, the FDA sent thousands of warning letters and approximately 100 cease-and-desist letters regarding non-compliant pharmaceutical advertising. This regulatory tightening benefits LUKE’s value proposition: practices need better compliance infrastructure, not less.
Consumer behavior has fundamentally shifted toward virtual-first healthcare. In 2024, more than 7 million prescriptions for controlled medications were issued via telemedicine without a prior in-person visit. Search volume for terms like “peptide therapy” and “GLP-1 injections” has surged, and patients increasingly expect the convenience of online consultations with home delivery of medications.
The cash-pay model is dominant in this space. TRT clinics typically charge $99–$200/month on subscription models without insurance involvement, creating high-margin businesses that value platform infrastructure over insurance billing capabilities.
The current infrastructure options for these practices are deeply inadequate. White-label telehealth platforms (Ola Digital Health, OpenLoop) provide clinical operations but own the provider network and patient relationship. Generic e-commerce platforms (Shopify, WooCommerce) have no Rx verification, no HIPAA compliance, and no clinical workflow integration. Healthcare CRMs (Salesforce Health Cloud, HubSpot) don’t connect to clinical data or commerce. Practice management systems (SimplePractice, Athena) are built for insurance-based primary care, not DTC commerce.
The result: practices stitch together 4–6 disconnected tools at a combined cost of $464–$2,299/month, with no unified data model, no single audit trail, and PHI scattered across multiple vendors with multiple BAAs.
LUKE’s beachhead market is telehealth practices specializing in hormone optimization: clinics delivering TRT, peptide therapy (BPC-157, Ipamorelin, CJC-1295, PT-141), GLP-1 weight management (semaglutide, tirzepatide), and broader hormone replacement therapy for both men and women.
This segment was selected through systematic evaluation of seven candidate verticals against LUKE’s architectural strengths. Hormone optimization clinics scored highest across all six evaluation criteria:
| Criterion | Hormone Clinics | Med Spas | Hybrid Clinical-Fitness | Primary Care | SARMs |
|---|---|---|---|---|---|
| All Domains Needed | ★★★★★ | ★★★ | ★★★★★ | ★★ | ★ |
| Rx Commerce Core | ★★★★★ | ★★ | ★★★ | ★ | ★ |
| Cash-Pay Model | ★★★★★ | ★★★★★ | ★★★★★ | ★★ | ★★★ |
| Market Growth | ★★★★★ | ★★★★★ | ★★★★★ | ★★★ | ✘ |
| Fitness/Wellness Fit | ★★★ | ★★ | ★★★★★ | ★ | ✘ |
| Regulatory Safety | ★★★★★ | ★★★★★ | ★★★★★ | ★★★★★ | ✘ |
SARMs — Eliminated. SARMs are not FDA-approved for human use. The FDA is actively pursuing criminal prosecutions of distributors, with multiple operators sentenced to federal prison in 2024–2025. As recently as December 2025, the FDA issued new warning letters. Building a SaaS platform around a category under active criminal enforcement creates existential brand and legal risk.
Primary Care — Wrong product-market fit. Primary care practices bill insurance, do video visits, and write referrals. They need EHR integration and claims processing, not Rx-gated commerce or lead scoring. LUKE’s six-domain architecture is overkill for their needs, and their actual needs (billing, EHR) aren’t what LUKE is built for.
Medical Aesthetics — Close but partial fit. Med spas are a $21B+ market growing at 16% CAGR, and some sell Rx skincare. However, 80%+ of revenue is service-based (Botox, fillers, laser), and product sales are add-on, not core. LUKE’s commerce engine is nice-to-have for med spas, not must-have. Strong adjacent expansion market.
Hybrid Clinical-Fitness — High-value expansion vertical. Sports medicine clinics, concierge practices with fitness components, functional medicine clinics offering movement therapy, and medically-supervised performance training facilities all need the same clinical-commerce-compliance infrastructure as hormone clinics, plus class scheduling, membership management, and fitness assessments. With LUKE’s Fitness & Wellness module, these hybrid operations replace both their clinical platform and their gym management software (Mindbody at $129–$699+/mo, Zen Planner at $99–$449/mo) with a single HIPAA-compliant system. Strong secondary beachhead.
The ideal first 25 LUKE tenants share the following characteristics:
The DTC telehealth hormone optimization segment within the United States encompasses an estimated 3,000–5,000 active practices. At LUKE’s Professional tier ($1,499/month plus usage-based expansion and 1.5% transaction fees), the segment represents an annual market opportunity of approximately $54M–$90M in platform subscription revenue alone, with additional transaction fee and expansion upside proportional to tenant growth.
A practice doing $100,000/month in product sales generates $1,500/month in transaction fees for LUKE on top of the platform subscription and expansion revenue — meaning high-performing tenants can generate $40,000+ in annual revenue per tenant. Capturing 5% of the beachhead (150–250 tenants) positions LUKE at $7–$12M in combined annual revenue.
LUKE is operationally ready for first-tenant launch. The platform is in active customer development across the hormone optimization beachhead market, with the deployment playbook documented and infrastructure provisioning rehearsed end-to-end.
Platform readiness: All six domains (clinical, commerce, CRM, platform/compliance, fitness/wellness, AI engagement) are deployed. Per-tenant encryption keys, audit trail, RLS isolation, breach detection, and onboarding wizards are live in the codebase and pass the launch checklist on dry-run.
Acquisition motion: Founder-led outreach to hormone optimization clinics, peptide therapy practices, and DTC men’s and women’s health brands in the beachhead segment. Initial discussions are ongoing; LUKE has zero paying customers as of this writing.
Case study target: Within 90 days of first-tenant go-live, LUKE will publish a case study documenting: number of disconnected tools consolidated (baseline: 4–6), time from sign-up to production go-live, compliance posture improvement (single BAA vs. multiple), operational hours saved per week, and commerce volume processed through the platform.
LUKE is a multi-tenant SaaS platform built on six integrated domains, each individually comparable to standalone products, but architecturally unified to eliminate the data fragmentation and compliance gaps that plague disconnected tool stacks.
Patient portal with demographics, medical history, and provider assignments. Appointment scheduling and telehealth integration. Prescription management with automated verification status tracking. Lab result tracking and treatment plan documentation. Secure provider-patient messaging with full audit trail. Health Gorilla FHIR R4 lab ordering with direct connectivity to LabCorp, Quest Diagnostics, and BioReference Laboratories. Getlabs at-home phlebotomy scheduling by ZIP code for specimen collection without office visits. LOINC compendium with 500+ standardized test codes for consistent lab ordering across networks. Biomarker trend tracking with configurable clinical alerts when results fall outside provider-defined thresholds. Patient notification preferences including callback email, chat transcripts, and daily digest options.
Rx-gated checkout: products requiring prescriptions cannot be purchased unless the patient has a verified, non-expired prescription from an authorized provider. Stripe-integrated payment processing with subscription support. Order lifecycle management (pending → verified → paid → processing → shipped → delivered). Invoice generation, refund handling, and coupon/discount engine. Webhook-driven fulfillment integration with pharmacy partners. Dose-variant pricing supporting different doses at different price points, each mapped to distinct Stripe products for accurate billing and inventory tracking. Dunning automation with configurable retry schedules for failed payments, reducing involuntary churn. SMS notifications via Twilio for appointment reminders, lab result availability, payment confirmations, and shipping updates with delivery tracking.
Algorithmic lead scoring (0–100) based on engagement signals, inquiry type, and behavioral indicators. Pipeline management with configurable stages (New → Contacted → Qualified → Consultation → Converted). Lead-to-patient conversion workflow that preserves CRM history while creating a clinical record. Bulk import from existing systems, conversion analytics, and source attribution.
Per-tenant AES-256-GCM authenticated encryption keys with configurable rotation schedules and crypto-shredding capability — deleting a tenant’s encryption key renders all their PHI permanently unrecoverable without touching a single database row. PostgreSQL row-level security policies enforcing tenant isolation at the database layer. Three-layer tamper-evident audit trail: SHA-256 hash-chained append-only log, a database trigger that rejects any insert which does not link cleanly to the prior row, and an off-database witness file (sealed with a kernel-level append-only attribute) reconciled against the live chain every hour. 64 distinct audit action types span authentication, PHI access, prescriptions, orders, and breach events. JWT authentication with MFA enforcement, breached-password detection (HIBP k-anonymity), and HIPAA-mandated session timeouts (15 minutes for patients, 30 minutes for staff). Role-based access control across 10 configurable roles with 55 granular permissions. Thirteen security headers enforced on every response (HSTS, Content-Security-Policy, X-Frame-Options, Referrer-Policy, and more). Rate limiting, TLS 1.3, and structured HIPAA-compliant logging with PHI scrubbed from all infrastructure logs. Automated breach detection monitoring four patterns in real-time: bulk PHI access, after-hours activity, failed authentication spikes, and unauthorized access attempts. Multi-state provider licensing support with credential verification and expiry tracking across jurisdictions. Feature flags per tenant enabling granular control over module availability, beta features, and tier-specific functionality. Launch checklist and onboarding wizards guiding new tenants through provisioning, configuration, compliance setup, and go-live verification.
Built-in compliance endpoints eliminate the need for third-party compliance monitoring tools: tamper-evident audit chain verification, PHI access reporting (who accessed what patient record, when, and from where), full patient data export for Right of Access requests (45 CFR §164.524), patient data deletion with transactional cascade and audit trail preservation, breach notification with HHS OCR guidance, and BAA records tracking with expiry management. Practices using LUKE replace $3,600–$7,500/year in standalone compliance tooling (Compliancy Group, Secureframe, Drata) with enforcement built directly into the platform.
Member self-service portal with class scheduling, session booking, trainer selection, fitness assessments, and progress tracking. Staff management tools including class and session management, attendance tracking, resource allocation, and instructor scheduling. Stripe-integrated membership billing with recurring payments, package management, cancellation handling, and proration. Check-in system with QR code and manual verification. Body composition tracking, functional movement assessments, and goal-based progress dashboards. Full HIPAA-compliant data handling—fitness data stored with the same per-tenant encryption and audit trail infrastructure as clinical records, critical for hybrid practices where workout data intersects with medical treatment plans. Designed for sports medicine clinics, concierge practices with fitness programs, medically-supervised training facilities, and any practice combining clinical services with wellness programming.
24/7 patient-facing AI agent adapted from a production system with nearly 100 live deployments. Chat widget embedded on the practice’s website and patient portal, trained on the practice’s specific services, pricing, providers, and policies. Voice phone agent answering inbound calls — handles appointment scheduling, prescription refill requests, service questions, and new patient intake, with intelligent handoff to clinical staff for complex or clinically significant inquiries. WhatsApp integration for patient communication on the platform they already use. Smart patient memory: first-time patients complete full intake; returning patients are identified and auto-filled, reducing friction for recurring visits and reorders. Bilingual support (English and Spanish) with additional languages configurable per tenant. Automated lead capture with real-time alerts to practice staff. Patient review solicitation tied to Google Business profiles. Structured data injection for SEO and AI search visibility. HIPAA-compliant conversation storage with per-tenant encryption, configurable retention policies, and full audit trail integration. All conversations, booking conversions, peak inquiry times, and common questions surfaced in an insights dashboard.
| Layer | Technology |
|---|---|
| Backend | Python 3.11, FastAPI, Uvicorn, asyncpg |
| Database | PostgreSQL 14 (self-hosted on Hetzner Cloud, isolated luke_health database) |
| Cache | Redis 7.0 (self-hosted on Hetzner Cloud) |
| Infrastructure | Hetzner Cloud (dedicated VM, Docker Compose orchestration, Tailscale-only management plane) |
| Payments | Stripe (Connect for multi-tenant payouts) |
| Security | Shared library cwad-platform-security (per-tenant encryption, hash-chained audit, witness reconciliation; see 5.4), per-environment secret files (/opt/cwad/.env), OpenTelemetry tracing, TLS 1.3 termination at nginx |
| Test Coverage | 432 tests across 31 files (unit, integration, security); GitHub Actions CI on every push and PR |
| Health Gorilla | FHIR R4 lab ordering network (LabCorp, Quest, BioReference) |
| Getlabs | At-home phlebotomy scheduling and specimen collection |
| Twilio | Transactional SMS notifications and delivery tracking |
The Rx Verification Gate is LUKE’s most defensible product feature. When a patient adds a prescription product to their cart, the commerce engine queries the clinical domain in real-time to verify that the patient has a current, non-expired prescription from an authorized provider for that specific product. If verification fails, the checkout is blocked and an audit event is recorded. This cross-domain coupling point is what makes LUKE fundamentally different from bolting Shopify onto a telehealth platform.
The audit trail provides mathematical proof of data integrity at three independent layers. Every event is cryptographically linked to the prior event using SHA-256 over its complete contents. The database itself rejects any insert that does not link cleanly to the prior row, so the chain cannot fork. An off-database witness file, sealed with a kernel-level append-only attribute, snapshots the chain state every hour and is reconciled against the live chain on the same cadence. When a regulator asks “who accessed this patient record and when?”, LUKE provides a single, tamper-evident chain of evidence verified across three controls, not logs scattered across four vendors.
LUKE’s compliance infrastructure replaces $300–$1,500/month in standalone HIPAA tools. Most telehealth practices in LUKE’s target market have significant compliance gaps visible from a surface-level scan: third-party tracking pixels firing on PHI pages, missing security headers, patient intake flowing through marketing CRMs without BAAs, and PHI scattered across vendors. LUKE eliminates these gaps architecturally — the Domain 4 capabilities described above are not optional add-ons but enforced defaults. Seven dedicated compliance API endpoints give practices audit-ready evidence they can present to regulators: a single, verifiable chain of custody for every patient record interaction.
The AI Engagement Layer is LUKE’s patient acquisition and retention accelerator. Unlike bolt-on chatbots that operate in isolation, LUKE’s built-in AI agent has full context across all six domains: it knows whether a patient has an active prescription, when their last appointment was, and what services their practice offers. When a returning patient calls at 9 PM to reorder their monthly TRT supply, the agent identifies them, verifies their prescription status, and processes the reorder — without a single staff member involved. This isn’t a chatbot. It’s the front door to the practice, connected to every system behind it.
The Fitness & Wellness Module bridges the gap between clinical infrastructure and wellness programming. No gym management platform (Mindbody, Zen Planner, Wodify) is HIPAA-compliant, and no clinical platform offers class scheduling, membership billing, or fitness assessments. LUKE is the only platform where a provider can view a patient’s body composition trends alongside their hormone panel results and prescription history—all under a single BAA, single audit trail, and single encryption architecture. For the growing category of hybrid clinical-fitness practices, LUKE doesn’t just replace tools—it eliminates the architectural gap between medical and wellness data that no combination of existing tools can solve.
The Lab Ordering Integration — Most telehealth platforms stop at prescriptions. LUKE continues into diagnostics. Health Gorilla provides FHIR R4 connectivity to major lab networks; Getlabs enables at-home specimen collection. The full order lifecycle — from provider order to patient notification — lives in one system. This is the kind of vertical integration that turns a prescription platform into a complete clinical workflow.
LUKE’s security primitives, the highest-risk code in any HIPAA platform, were extracted in May 2026 into a separately versioned internal library, cwad-platform-security. LUKE consumes the library as a pinned dependency. Per-tenant encryption, hash-chained audit logging, witness reconciliation, RBAC, anomaly detection scaffolding, and security-headers middleware all live in one auditable place rather than being duplicated across products.
The business consequence is that compliance cost compounds across products rather than per product. When a CVE lands, when an auditor flags a finding, or when an underlying algorithm needs to rotate, the fix happens once and propagates to every consumer via a version bump. The first product (LUKE) absorbed the cost of building HIPAA-grade security infrastructure. The next product on this stack inherits it on its first commit.
The migration moved approximately 830 lines of security-critical code out of the LUKE repository while keeping every caller’s public API surface byte-identical. No LUKE feature changed, no test was rewritten, and no behavior regressed in production. LUKE runs on tag 0.1.0a2 today. The package is private, hosted on internal GitHub, version-pinned, and CI-tested against LUKE on every push. The package repository, version tags, migration commits, and CI history are available to a technical due-diligence reviewer under NDA.
| Module | Scope |
|---|---|
| crypto | Per-tenant AES-256-GCM field encryption, MultiFernet legacy decryption, key rotation, crypto-shredding for right-to-erasure, pluggable key resolver and secrets provider |
| audit | Per-tenant SHA-256 hash chain with Postgres advisory locks, canonical-JSON payload coverage, Redis Stream durable retry queue, hourly off-database witness file with kernel-level append-only protection, Redis-backed sliding-window failure alerting, per-tenant chain bootstrap on resume |
| Reusable primitives | RBAC with dual-wildcard matching, anomaly detection framework, deletion-plan executor, security-headers middleware, rate-limiter scaffolding (wired into the package, ready for the next consumer) |
| Feature | Starter | Professional | Enterprise |
|---|---|---|---|
| Monthly Price | $799/mo | $1,499/mo | $3,499/mo |
| Annual Price | $679/mo | $1,274/mo | $2,974/mo |
| Onboarding Fee | $2,500 | $5,000 | Custom |
| Providers Included | 2 (+$75/mo each additional) | 5 (+$50/mo each additional) | Unlimited |
| Patients | 500 | 2,500 | Unlimited |
| CRM Leads | 1,000 | 5,000 | Unlimited |
| AI Conversations | 500/mo | 2,000/mo ($0.10/overage) | 5,000/mo ($0.08/overage) |
| Voice Minutes | Not included | 200 min ($0.20/overage) | 500 min ($0.15/overage) |
| Encryption | Shared | Per-Tenant Keys | Dedicated + Custom Rotation |
| White Label | Co-branded | Full White Label | Full White Label |
| Support SLA | Email (24hr) | Priority (4hr) | Dedicated (1hr) |
| Fitness Module | Classes + Check-in | Full Suite + Assessments | Full Suite + Custom Workflows |
All tiers include HIPAA compliance, BAA, 1.5% transaction fee on e-commerce volume, and 14-day free trial (Starter tier, 50-patient cap, no credit card required).
LUKE operates a hybrid revenue model combining five streams:
A typical hormone optimization practice currently pays the following for disconnected tools:
| Tool Category | Monthly Cost | LUKE |
|---|---|---|
| Telehealth Video Platform | $35–$100 | ✓ Built-in |
| Healthcare CRM | $100–$800 | ✓ Built-in |
| E-Commerce + Rx Checkout | $79–$599 | ✓ Built-in |
| HIPAA Compliance Tooling | $300–$1,500 | ✓ Built-in |
| Email / Marketing Platform | $50–$300 | ✓ Built-in |
| AI Chatbot / Answering Service | $150–$500 | ✓ Built-in |
| Fitness / Gym Management Software | $79–$699 | ✓ Built-in |
| Combined Monthly Spend | $793–$4,498 | $1,499 (Professional) |
At the Professional tier, LUKE replaces $793–$4,498/month in fragmented tooling with a single platform at $1,499/month. The key distinction: standalone compliance tools only monitor — LUKE enforces. And standalone fitness platforms are not HIPAA-compliant, forcing hybrid practices to maintain separate systems with no clinical data integration.
LUKE’s competitive position is defined by what it is not. It is not a white-label telehealth provider, not a generic e-commerce platform, not a gym management app, and not a practice management system. It is multi-tenant infrastructure for practices that need all six domains working together.
| Capability | LUKE | Bask Health | Healthie / Jane | Hims & Hers | Wheel / Truepill | Mindbody | DIY Stack |
|---|---|---|---|---|---|---|---|
| Price Range | $799–$3,499/mo | Contact sales | $25–$149/mo | DTC (N/A) | Per-consult/API | $129–$699/mo | $793–$4,498/mo |
| Rx-Gated Checkout | ✓ | Partial | ✘ | Internal | ✘ | ✘ | ✘ |
| Own Your Patient Data | ✓ | Partial | ✓ | ✘ | ✘ | N/A | ✓ |
| Per-Tenant Encryption | ✓ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| Hash-Chained Audit | ✓ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| Built-in CRM | ✓ | ✘ | Basic | Internal | ✘ | Partial | Separate |
| Lead-to-Patient Flow | ✓ | ✘ | ✘ | N/A | ✘ | ✘ | ✘ |
| White Label Portal | ✓ | ✓ | ✓ | ✘ | ✓ | ✘ | ✓ |
| Fitness / Class Management | ✓ | ✘ | ✘ | ✘ | ✘ | ✓ | Separate |
| Clinical + Fitness Integration | ✓ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| Advertising Intelligence | ✓ (Artemis) | ✘ | ✘ | Internal | ✘ | Marketplace | ✘ |
| AI Patient Agent | ✓ | ✘ | ✘ | Internal | ✘ | ✘ | ✘ |
| FHIR Lab Ordering | ✓ | ✘ | ✘ | Internal | ✘ | ✘ | ✘ |
| Clinician Network | ✘ | ✘ | ✘ | ✓ | ✓ (Wheel) | ✘ | ✘ |
| Pharmacy Fulfillment | Partner | ✓ | ✘ | ✓ | ✓ (Truepill) | ✘ | ✘ |
| Crypto-Shredding | ✓ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| Automated Breach Detection | ✓ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ |
| No Setup Fees | ✘ | ✓ | ✓ | N/A | ✓ | Varies | N/A |
Honest competitive analysis requires acknowledging where competitors are strong, not just where they fall short. LUKE does not win by pretending competitors are weak. It wins because its target customer — hybrid clinical-commerce-fitness practices — has needs that no single competitor addresses.
What they do well: Bask Health has built the most credible “Shopify for Telehealth” product on the market. They power 100+ telehealth companies with a white-label, no-code platform that handles patient intake, e-prescribing, and pharmacy fulfillment in a single system. They are HIPAA-compliant, SOC 2 certified, Surescripts and LegitScript integrated. Their no-setup-fee model reduces time-to-value — an entrepreneur can launch a branded DTC telehealth company on Bask without writing a line of code. They have seed funding ($760K) from Emerald Bioventures and Third Act Ventures and are actively growing their customer base in the DTC telehealth space. For a non-clinical founder launching a branded telehealth brand from scratch, Bask Health is a strong option.
Where LUKE wins: Bask’s architecture does not support per-tenant encryption or hash-chained audit trails. These are foundational architectural decisions made at the database and cryptographic layer — not features that can be patched in. Retrofitting per-tenant encryption onto a shared-key architecture requires re-encrypting all existing tenant data, rebuilding the key management system, and modifying every data access path. Bask also lacks a built-in CRM with lead scoring, pipeline management, and lead-to-patient conversion workflows, meaning their customers still need a separate CRM, which reintroduces the fragmentation problem. LUKE also offers fitness management, AI engagement (chat + voice + WhatsApp), and advertising intelligence (Artemis) — none of which Bask provides. Most importantly, Bask serves brands that don’t have their own providers. LUKE serves practices that already have providers and patients and need infrastructure, not a clinician network.
What they do well: Mindbody is the dominant platform in fitness and wellness management by a wide margin. Acquired by Vista Equity Partners for $1.9 billion in 2019, the platform serves 60,000–65,000 businesses and operates a consumer marketplace with 2.4 million active users who discover and book fitness classes, spa appointments, and wellness services. That marketplace is a distribution channel no competitor can replicate — businesses on Mindbody get discovered by consumers actively searching for fitness services. Their scheduling engine is mature, their mobile apps are polished, and their brand recognition in the fitness industry is unmatched. Major chains like Massage Envy, Pure Barre, and CorePower Yoga run on Mindbody. With 1,400+ employees and Vista’s backing ($70B+ AUM), they have resources to invest in product development at a scale no startup can match.
Where LUKE wins: Mindbody was built for pure fitness and wellness businesses. It is not HIPAA-compliant, does not support clinical workflows, Rx verification, patient records, or audit trails. A sports medicine clinic or medically-supervised training facility cannot run its clinical operations on Mindbody. These practices currently pay for Mindbody and a separate clinical platform, with no integration between a patient’s medical treatment plan and their fitness programming. LUKE eliminates this gap. It does not compete with Mindbody for yoga studios or spin chains — it competes for the hybrid clinical-fitness practices that Mindbody was never designed to serve.
What they do well: Zen Planner (owned by Daxko, a publicly traded fitness software company) dominates boutique fitness: CrossFit boxes, martial arts studios, and small specialty gyms. Their member retention tools, belt/rank tracking, and mobile-first member app are purpose-built for these niches. Wodify owns the CrossFit affiliate ecosystem with 5,000+ gyms, offering WOD programming, real-time leaderboards, competition management (Wodify Arena), and community engagement features that drive member retention — members who track performance are 3x more likely to renew. Both platforms have deep expertise in their respective fitness verticals, competitive pricing ($79–$449/mo), and loyal user communities that value sport-specific features over generalist platforms.
Where LUKE wins: Same fundamental gap as Mindbody: neither platform is HIPAA-compliant or supports clinical operations. A functional medicine clinic that adds CrossFit-style group training cannot run both operations on Zen Planner or Wodify. These platforms also lack Rx-gated checkout, CRM with lead-to-patient conversion, AI patient engagement, or advertising intelligence. LUKE’s fitness module may not have Wodify’s leaderboard depth or Zen Planner’s belt tracking, but it is the only platform where fitness programming integrates with clinical records under unified HIPAA-compliant infrastructure.
What it does well: The Shopify ecosystem is massive and flexible. Twenty-five healthcare brands are actively using Shopify for wellness e-commerce, with HIPAA-compliant apps available for patient communication, scheduling, and basic telehealth. The platform’s developer community, third-party plugin marketplace, and enterprise tier (Shopify Plus) make it possible to build a custom health commerce operation with relatively low lock-in. Combined with SimplePractice (250,000+ therapists, de facto standard for mental health EHR) or Jane App (popular among allied health practitioners), a technically capable operator can assemble a functional stack at lower monthly cost than a purpose-built platform.
Where LUKE wins: A DIY stack trades upfront cost savings for permanent operational complexity. Each tool requires a separate vendor relationship, a separate BAA, and a separate prayer that patient data stays consistent. HIPAA compliance is handled at the app layer, not the platform layer — meaning the practice is responsible for auditing every integration point. There is no unified audit trail, no cross-domain data model, no single-query access to a patient’s clinical history, commerce transactions, CRM status, and fitness activity. Most critically, a DIY stack cannot deliver Rx-gated checkout (real-time prescription verification before purchase), lead-to-patient conversion workflows, or AI agents with full clinical context. The “savings” disappear when the practice accounts for integration maintenance, compliance gaps, and the staff hours spent context-switching across four to six separate tools.
White-label telehealth providers like Ola Digital Health and OpenLoop solve a different problem entirely: they provide the clinical network and operational infrastructure for brands that don’t want to manage their own providers. They are strong at what they do — enabling non-clinical founders to launch branded telehealth brands quickly. But LUKE serves practices that already have providers and patients. These practices need infrastructure, not clinicians. There is minimal competitive overlap.
What they do well: These platforms dominate the $25–$149/month practice management tier for health and wellness practitioners. Healthie ($59–$149+/mo) serves dietitians and virtual-first practices with solid telehealth, scheduling, and insurance billing. Jane App ($54–$99/mo per practitioner) is the go-to for allied health — physiotherapists, chiropractors, massage therapists — with polished scheduling and clinical charting. Practice Better ($25–$89/mo) owns the health coaching niche with protocol builders and Fullscript supplement dispensary integration. All three are HIPAA-compliant with BAA coverage, have mature UX, and serve tens of thousands of practitioners.
Where LUKE wins: None of these platforms support prescription-gated commerce, integrated CRM with lead scoring, AI patient engagement, or fitness management under a single HIPAA architecture. They are point solutions for scheduling and charting — not infrastructure for practices selling prescription products online. A hormone optimization clinic using Jane App still needs separate tools for e-commerce, CRM, compliance, and patient communication. LUKE replaces the entire stack. The pricing difference ($54–$149/mo vs. $799–$3,499/mo) reflects a fundamentally different value proposition: per-seat practice tools vs. a full-stack commerce platform. VCs will ask “why not just use Jane App?” — the answer is that Jane App has no answer for Rx-gated checkout, AI agents with clinical context, or commerce attribution.
What they do well: Hims & Hers is the category-defining DTC telehealth company — publicly traded, ~$2.5B+ annual revenue run rate by early 2026, 2M+ subscribers. They own the entire vertical: consumer brand, async telehealth consultations, in-house compounding pharmacy, and subscription fulfillment across sexual health, hair loss, weight management (GLP-1), dermatology, and mental health. Their vertical integration gives them margin control and brand recognition that no startup can match.
Where LUKE wins: Hims is not a competitor — it is a cautionary tale and a validation signal. Hims competes with independent practices; LUKE empowers them. LUKE exists because thousands of clinicians want to run their own DTC telehealth businesses without being absorbed into Hims’s model. The independent practice that uses LUKE keeps its brand, its patients, and its clinical relationships. Hims also faces significant FDA regulatory risk on compounded GLP-1s (enforcement tightened in 2025–2026), while LUKE’s compliance architecture is designed to help practices survive exactly that enforcement environment.
What they do well: Wheel ($250M+ raised, clinician network in all 50 states) and Truepill ($256M raised, API-based pharmacy fulfillment) are genuine infrastructure companies. Wheel provides a clinician marketplace — companies plug into Wheel to add licensed providers without building a clinical operation. Amazon Clinic is a major customer. Truepill enables digital pharmacy fulfillment via API, handling prescription dispensing and shipping for DTC brands.
Where LUKE wins: Both are single-layer infrastructure — consults (Wheel) or pharmacy (Truepill) — sold to DTC brands adding health features. Neither offers CRM, patient engagement AI, fitness management, or clinical workflow tooling. LUKE targets a different buyer: clinicians and practices running their own telehealth businesses, not DTC brands outsourcing clinical operations. The more interesting relationship is as potential integration partners — LUKE could use Wheel’s clinician network for overflow coverage or Truepill’s fulfillment APIs as a pharmacy backend, adding infrastructure depth without building those layers internally.
No competitor operates an integrated advertising intelligence platform. Bask Health can help practices manage patients and sell products, but cannot help them find patients. Mindbody’s marketplace provides consumer discovery for fitness classes, but does not help clinical practices acquire patients for medical services. LUKE, combined with Artemis Targeting, offers a closed loop from patient acquisition through commerce and retention. This is a structural advantage that cannot be replicated by adding a feature — it requires building and operating a second platform.
No competitor offers an integrated AI engagement layer with clinical context. Practices using Bask Health, Mindbody, or a DIY stack still need a separate chatbot or answering service — one that has no access to clinical data, prescription status, fitness history, or CRM context. LUKE’s AI agent operates within the platform with full context across all six domains (see Section 5.3 for detailed capabilities). The competitive difference: bolt-on chatbots answer generic questions; LUKE’s agent checks prescription status, processes reorders, and books appointments with real clinical data behind every response.
This is the gap no existing platform fills. Bask Health does telehealth commerce but not fitness. Mindbody does fitness management but not clinical. No competitor offers both under a single HIPAA-compliant architecture. The growing category of hybrid clinical-fitness practices — sports medicine clinics, concierge practices with fitness memberships, functional medicine clinics offering movement therapy — currently stitches together a clinical platform and a gym management platform with no data integration between them. LUKE unifies both, so a provider can view body composition trends alongside hormone panels and prescription history in one system.
No competing telehealth SaaS platform at LUKE’s price point offers integrated FHIR lab ordering with at-home collection. Established players like Athenahealth and DrChrono require separate lab integrations and third-party middleware. LUKE’s Health Gorilla integration is native — lab orders, results, biomarker tracking, and patient notifications all share the same database. The switching cost for a practice using LUKE’s lab ordering is significantly higher than one using it only for telemedicine.
Investors and prospects deserve a competitive assessment that acknowledges reality, not one that overstates strengths and ignores gaps. This section addresses both.
The gap between LUKE’s architectural strength and its commercial position closes with three milestones:
LUKE’s bet is that its disadvantages are temporary (brand recognition, customer count, team size will improve with traction and revenue) while its structural advantages are permanent (per-tenant encryption, hash-chained audit, clinical-fitness integration, and the Artemis flywheel are architectural decisions that cannot be easily replicated). The product is real. The architecture is genuinely strong. The gap is market validation — and that gap closes with execution, not features.
The first ten tenants will be acquired through direct outreach, conference presence, and first-customer reference selling once the initial case study is in market. This is a founder-led sales motion, not a marketing funnel.
Cullari & Wardell’s existing Artemis Targeting platform provides LUKE with a distribution advantage no competitor can replicate. This is not a theoretical synergy — it is a closed-loop flywheel where both platforms make each other more valuable.
The flywheel now spans three products. Artemis drives patient leads through geotargeted advertising across 4,260+ demographic and behavioral segments. LUKE’s AI Agent captures and qualifies those leads 24/7 across chat, voice, and WhatsApp — converting website visitors and inbound callers into booked consultations while practice staff sleep. LUKE’s clinical, commerce, and CRM domains then convert qualified leads through prescription verification, Rx-gated checkout, and pipeline management. Transaction fee revenue from LUKE-powered commerce validates Artemis campaign ROI in hard dollars — not click metrics, but actual prescriptions filled and products shipped. Practices see this closed-loop attribution and increase their Artemis spend. All three products compound each other’s value.
A hormone optimization clinic already using Artemis for geotargeted patient acquisition is the ideal LUKE prospect. They’ve already bought into Cullari & Wardell’s technology approach, proven their willingness to invest in growth infrastructure, and established a trust relationship with the company. The sales conversation shifts from “trust us with your practice infrastructure” to “let us connect your advertising to your commerce.”
Practices running both Artemis and LUKE generate a unique feedback loop. Artemis targeting data reveals which patient demographics and geographic segments respond to campaigns. LUKE commerce data validates which of those segments actually convert into paying, recurring patients. This intelligence flows back into Artemis to optimize future campaigns — a capability no competitor can offer because no competitor operates both an advertising intelligence platform and a practice management platform.
Artemis clients are warm leads for LUKE. The trust relationship, vendor familiarity, and demonstrated technical competence are already established. Estimated CAC for Artemis-sourced LUKE tenants: $500–$1,500, compared to $2,500–$5,000 for cold acquisition. At the Professional tier ($21,000/year ARPT), this yields a CAC payback period of less than one month and an LTV:CAC ratio exceeding 70x. Even conservatively, the Artemis channel dramatically improves already-strong unit economics.
Cullari & Wardell is the only company in the market that operates all three layers — advertising intelligence (Artemis), patient engagement (AI Agent), and practice infrastructure (LUKE, including clinical, commerce, fitness, CRM, and compliance) — as a single integrated system. Competitors address one layer at best. The result is a closed-loop ecosystem where each product makes the other two more valuable. No practice can replicate this by stitching together three separate vendors, because the value comes from the shared data model and unified context that only a single-platform approach provides.
Transition from founder-led sales to a repeatable inbound motion with outbound supplement.
Compounding pharmacies are the fulfillment backbone for LUKE’s target clinics. They have direct, trusted, recurring relationships with exactly the ICP — the hormone optimization practices that need LUKE’s infrastructure.
A pharmacy benefits directly from their client clinics adopting LUKE: it means structured, API-driven order workflows replacing faxes, phone calls, and manual prescription verification. Order accuracy improves. Fulfillment velocity increases. The pharmacy’s operations become more efficient because their clients’ operations become more efficient.
A single compounding pharmacy relationship that refers 10–20 clinics is dramatically more efficient than individual outreach. Potential co-marketing as a “Recommended technology partner” with major compounding pharmacies creates a scalable, trust-based channel.
This channel also provides market intelligence. Pharmacies know which clinics are growing, which are struggling with operational complexity, and which are actively evaluating better tooling. This information is invaluable for timing outreach and tailoring the sales conversation.
Expand concentrically from the beachhead into adjacent verticals: med spas with Rx skincare lines, functional medicine practices with supplement commerce, compounding pharmacies building their own DTC brands, sports medicine clinics with performance training programs, concierge practices combining medical oversight with fitness memberships, and medically-supervised wellness facilities. The Fitness & Wellness module opens an entirely new expansion lane into hybrid clinical-fitness operations — a growing category of practices that no existing platform serves comprehensively.
The 15% industry-average churn rate applies to typical single-domain vertical SaaS where switching costs are low. LUKE’s churn dynamics are structurally different. The platform stores clinical records, patient histories, prescription data, commerce transaction history, fitness assessments, class attendance, membership billing, CRM pipeline, and audit trails in a single system with per-tenant encryption. Migration requires extracting and re-importing data across 5+ replacement tools, re-signing multiple BAAs, rebuilding compliance infrastructure, and accepting an audit trail gap during transition. Year 1 models conservatively at 15% while the product matures and onboarding processes are refined. Years 2–5 model at 10% based on expected switching cost dynamics and the deepening data lock-in that occurs as tenants accumulate patient records and transaction history.
The AI engagement and fitness layers add additional switching-cost dimensions. A practice dependent on LUKE for clinical workflows, commerce, fitness programming, CRM, compliance, and patient communication — with trained AI agents that know their services, pricing, and patient history, and fitness data interlinked with clinical records — faces even higher migration friction than a four-domain model alone.
The growth from 25 tenants (Year 2) to 80 tenants (Year 3) requires the following conditions:
| Assumption | Value | Basis |
|---|---|---|
| Sales cycle length | 30–60 days | Professional tier; founder-led closing |
| Pipeline-to-close ratio | 3:1 | Qualified opportunities to signed tenants |
| Required pipeline (Year 3) | ~165 qualified opps | 55 new tenants × 3:1 ratio |
| Channel mix | 40% inbound/SEO, 25% Artemis, 20% pharmacy, 15% direct | Phase 2 engine maturation |
| Hiring dependency | Year 2 eng hire frees founder for sales | Inbound engine producing by Month 12 |
The Artemis cross-sell channel is the key accelerant: it provides warm leads at dramatically lower CAC, shortening the sales cycle and improving conversion rates. The compounding pharmacy channel provides batch introductions (10–20 clinics per relationship) that are more efficient than individual outreach.
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| New Tenants | 5 | 22 | 60 | 105 | 130 |
| Active Tenants (EOY) | 5 | 25 | 80 | 175 | 275 |
| Subscription ARR | $102K | $510K | $1.6M | $3.6M | $5.6M |
| Platform Expansion (Seats + AI) | $8K | $55K | $220K | $530K | $1.0M |
| Onboarding Revenue | $19K | $88K | $240K | $420K | $520K |
| Transaction Fee Rev | $27K | $320K | $1.4M | $3.2M | $5.8M |
| Total Revenue | $155K | $970K | $3.5M | $7.7M | $12.9M |
| Expense Category | Year 1 | Year 3 |
|---|---|---|
| Cloud Infrastructure (Hetzner) | $18K | $72K |
| Stripe Processing Fees (2.9%+30¢) | $5K | $110K |
| Anthropic AI API | $6K | $24K |
| Sales & Marketing | $12K | $180K |
| Engineering (contractor/hires) | $0 | $240K |
| Legal / Compliance | $8K | $24K |
| Total Operating Costs | $49K | $650K |
Year 1 is lean by design: founder-led sales, no engineering hires, minimal marketing spend. The platform is already built and in production. Profitability is projected by Month 6 at 3 active tenants. Year 3 operating costs scale with headcount as the company adds engineering and support capacity.
At the Professional tier with average e-commerce volume:
Average Revenue Per Tenant (ARPT): $32,000/year ($1,499/mo subscription + $150/mo seat expansion + $150/mo AI overages + $900/mo transaction fees)
Customer Acquisition Cost (CAC): $2,500–$5,000 (cold); $500–$1,500 (Artemis-sourced)
CAC Payback Period: 1–2 months (cold); <1 month (Artemis-sourced)
Lifetime Value (LTV): $192,000 (5-year average at 10% annual churn, Years 2+)
LTV:CAC Ratio: 38–77x (cold acquisition); 128–384x (Artemis-sourced)
Co-founder and CEO of Cullari & Wardell, and the sole architect and developer of the company’s entire technology stack. Ernesto personally wrote every line of production code across all three platforms: Artemis Targeting, the CW/AD AI Agent platform, and LUKE. All three run on the same proven technical stack — Python/FastAPI, PostgreSQL, Redis, Hetzner Cloud (Docker Compose), OpenTelemetry — designed, built, and maintained by a single technical founder.
Published writer, commercial photographer, and experienced creative director with seventeen years of writing experience. Prior experience across healthcare, biotech, financial services (NASDAQ/IRPR firms), and direct-to-consumer brands. This combination of hands-on engineering and creative/strategic background is what enables a single founder to architect the platform, write the code, position it in market, and sell it — without separate teams for each function.
Co-founder and partner of Cullari & Wardell. Brings operational leadership and strategic direction to the company’s growth initiatives. As co-owner, Barbara provides executive oversight across business development, client relationships, and organizational strategy — ensuring that the company’s rapid technical execution is matched by disciplined business operations.
Software developer supporting ongoing platform development and maintenance. With the core architecture and codebase established by Ernesto, Noah adds engineering capacity for feature implementation, bug fixes, and frontend work across Cullari & Wardell’s product portfolio.
All three platforms were architected and coded by Ernesto Cullari using an AI-augmented development workflow powered by Claude Code, enabling a solo technical founder to operate at the output level of a much larger engineering organization. This is not a stopgap — it is the operational model.
Evidence of sustained output:
Additional engineering hires in Year 2 will add capacity for development velocity and frontend/tenant experience improvements — not because the current team cannot maintain the platform, but because growth demands building faster than a lean team can ship, even with AI augmentation.
Phase 1 (Year 1): Founding team (two partners + one developer) with AI-assisted development (Claude Code for parallel implementation). Phase 2 (Year 2): Additional engineering hire focused on frontend/tenant experience. First customer success hire for onboarding and support. Phase 3 (Year 3): Full engineering team (3–4), dedicated sales hire, compliance officer.
| Risk | Impact | Mitigation |
|---|---|---|
| DEA telemedicine flexibilities expire | Reduces telehealth-only practice viability | LUKE supports hybrid (in-person + virtual) models; 4 bills in Congress for permanent extension |
| Bask Health or new entrant matches features | Price pressure, feature parity | Core compliance architecture is hard to retrofit (see Section 5); CRM integration is deep moat; Artemis distribution channel is unreplicable |
| Slow tenant acquisition | Extended path to profitability | Year 1 breakeven at 4 tenants; low fixed costs; founder can sustain via Artemis/agency revenue independent of LUKE growth timeline |
| Key-person risk | Development bottleneck, operational risk | Two co-founders plus a dedicated developer reduce single-point-of-failure risk. AI-augmented development model. Automated CI/CD, deployment integrity scripts, and comprehensive test suite enforce correctness independent of any single operator. Incident response codified in operational runbooks. |
| FDA enforcement tightening | Regulatory burden on tenants | LUKE’s compliance infrastructure is a moat in tighter regulatory environments; more enforcement = more demand for proper tooling |
| AI agent voice/chat quality or hallucination | Patient misinformation, compliance exposure | Knowledge bases curated per-tenant with practice-specific data only; clinical escalation protocols route sensitive inquiries to licensed providers; conversation audit trails enable rapid review; system refined across nearly 100 production deployments before healthcare adaptation |
| HIPAA breach | Legal liability, reputational damage | Automated breach detection with real-time monitoring (see Section 5). Per-tenant encryption limits blast radius to a single tenant. Hash-chained audit provides tamper-evident forensic evidence. HHS notification tracking and 7 compliance endpoints built in. Annual penetration testing planned. |
| Health Gorilla / Getlabs API dependency | Lab ordering feature unavailable if APIs go down | FHIR R4 is an open standard — lab networks are substitutable. Getlabs has competitors (Scarlet, Phlebfinders). Queue-based architecture means orders retry automatically. |
| Timeline | Milestone | Status |
|---|---|---|
| Q4 2025 | Platform audit: 58 findings remediated, 300+ tests passing | ✓ Complete |
| Q1 2026 | Fitness & Wellness module deployed (Domain 5) | ✓ Complete |
| Q1 2026 | Health Gorilla FHIR lab ordering integration (LabCorp, Quest, BioReference) | ✓ Complete |
| Q1 2026 | Getlabs at-home phlebotomy integration | ✓ Complete |
| Q1 2026 | SMS notifications via Twilio (appointments, results, payments) | ✓ Complete |
| Q1 2026 | Automated breach detection (4 patterns: bulk PHI, after-hours, failed auth, unauthorized access) | ✓ Complete |
| Q1 2026 | Multi-state provider licensing support | ✓ Complete |
| Q1 2026 | AI agent self-service: prescription status, order tracking, lab results via chat | ✓ Complete |
| Q1 2026 | Chat-based patient registration and provider messaging relay | ✓ Complete |
| Q1 2026 | Proactive chat notifications: appointment reminders, lab alerts, payment notices | ✓ Complete |
| Q2 2026 | First tenant launched and case study published; tenants 2–3 onboarded; first hybrid clinical-fitness tenant targeted | Planned |
| Q3 2026 | 5 active tenants; breakeven achieved; pricing validated | Planned |
| Q4 2026 | 10 tenants; first conference presence (A4M / AMMG) | Planned |
| H1 2027 | 25 tenants; first engineering hire; inbound marketing engine live | Planned |
| H2 2027 | 50 tenants; expand into med spa and hybrid clinical-fitness verticals; API partner program | Planned |
| 2028 | 75–100 tenants; full team (engineering, sales, CS, compliance) | Planned |
How a $20,000 Telehealth Startup Reached $1.8 Billion — and Why It Proves the Case for LUKE
April 2026 • Based on The New York Times, Forbes, Techdirt, and independent analysis
In April 2026, The New York Times profiled Medvi — a telehealth company founded by Matthew Gallagher with $20,000 in startup capital and two employees (himself and his brother). In its first full year, Medvi generated $401 million in verified revenue serving 250,000 patients, primarily through GLP-1 weight-loss prescriptions at $179/month. The Times projected the company to reach $1.8 billion in 2026 revenue, calling it the closest real-world example of Sam Altman’s predicted “one-person billion-dollar company.”
The story went viral. Forbes, Inc., PYMNTS, Yahoo Finance, and dozens of outlets followed with their own coverage. It validated, at unprecedented scale, two things LUKE is built on: (1) AI-augmented teams can build billion-dollar healthcare businesses, and (2) the demand for accessible telehealth infrastructure is massive and accelerating.
But within days, the narrative shifted. Techdirt ran the headline: “The New York Times Got Played By A Telehealth Scam And Called It The Future Of AI.” Independent investigators surfaced an FDA warning letter, BBB complaints over billing and cancellation practices, and reports of a data breach. Medvi proved the market opportunity is real — and simultaneously proved what happens when you build a billion-dollar healthcare business without proper compliance infrastructure.
Medvi is a marketing and acquisition frontend. Gallagher outsourced the entire medical operation — licensed providers, pharmacy fulfillment, prescription management, shipping, and clinical compliance — to third-party platforms (CareValidate and OpenLoop Health). He used generative AI (ChatGPT, Claude, Grok) for ad copy, landing pages, customer service automation, and analytics.
The core business model: acquire patients through Meta and Google advertising, route them to outsourced telehealth providers, and collect $179/month per subscription. Medvi owns no medical infrastructure, employs no clinical staff, and holds no proprietary technology beyond its marketing operation.
Key detail: In February 2026, the FDA issued Medvi a warning letter for misleading marketing practices, including AI-generated before-and-after imagery. This is not incidental — it is a direct consequence of a business model built entirely on acquisition with no compliance infrastructure of its own.
Independent analysis (Techdirt, Hacker News, The Decoder, NewClaw Times) converged on the same set of structural risks:
LUKE is what companies like Medvi should be running on. The comparison is not competitive — it is structural. Medvi is a customer archetype; LUKE is the operating system.
| Dimension | Medvi | LUKE |
|---|---|---|
| What it is | Marketing funnel → white-label telehealth | Full SaaS platform (6 integrated domains) |
| Owns the stack | No — outsources clinical, fulfillment, compliance | Yes — clinical, commerce, CRM, compliance, fitness, AI |
| Revenue model | DTC drug subscriptions ($179/mo per patient) | B2B SaaS ($799–$3,499/mo per practice) + seat expansion + AI usage + 1.5% transaction fees |
| Compliance | Outsourced to third-party providers | Per-tenant AES-256-GCM authenticated encryption, three-layer tamper-evident audit (hash-chain + DB trigger + off-database witness), RLS, crypto-shredding, 64 audit action types, automated breach detection |
| Switching costs | None — patients leave freely | High — 6-domain integration creates deep lock-in |
| AI integration | Ad copy generation, basic chatbot | AI patient engagement agent (100+ deployments), proactive notifications, self-service Rx/lab/order tracking |
| Lab integration | None (outsourced) | Native FHIR R4 (LabCorp, Quest, BioReference, Getlabs at-home phlebotomy) |
| Customers | 250K consumers buying GLP-1 drugs | B2B: practices and clinics (12K–18K TAM) |
| Regulatory risk | FDA warning letter (Feb 2026); no internal compliance tooling | Compliance is the product — enforcement tightening strengthens the moat |
| Employees | 2 | 3 (founder-led, AI-augmented development) |
$401 million in Year 1 from a two-person team is not a fluke — it is a demand signal. The hormone therapy, GLP-1, and peptide clinic market is flush with revenue and growing. These are the exact practices LUKE targets at the Professional and Enterprise tiers. Medvi proved they have money to spend; LUKE gives them something worth spending it on.
The Medvi FDA warning letter is not an isolated incident — it is the leading edge of regulatory tightening across telehealth. Practices that outsource compliance (the Medvi model) are exposed. Practices that embed compliance into their operating system (the LUKE model) are protected. Per-tenant encryption, hash-chained audit trails, automated breach detection, and crypto-shredding are not features competitors can bolt on after the fact. This is architectural.
| Metric | Medvi (DTC) | LUKE (B2B SaaS) |
|---|---|---|
| Revenue per customer/year | ~$2,148 (patient @ $179/mo) | ~$32,000 (tenant @ Professional tier incl. seat and AI expansion) |
| Transaction fee upside | None | 1.5% on e-commerce volume ($60K/mo in orders = $10,800/yr additional) |
| Customer acquisition | Paid media (Meta/Google), high CAC | Founder-led sales, conference presence, case studies |
| Churn risk | High — patients switch on price | Low — 6-domain integration creates switching costs |
| Margin profile | 16.2% (no infrastructure = low cost, but no leverage) | 75%+ gross margin at scale (SaaS economics) |
One LUKE tenant generating $60,000/month in patient orders produces $10,800/year in transaction fees on top of ~$21,000 in platform subscription and expansion revenue. And LUKE tenants bring their own patients, eliminating the DTC acquisition cost entirely.
Medvi spends on Meta and Google ads to acquire patients. LUKE practices get a fundamentally different growth engine:
This is a closed loop: targeting → engagement → conversion → revenue → measurable ROI. Medvi has step one (spend money on ads) and step three (sell subscriptions). LUKE has all four, instrumented end-to-end.
The New York Times ran the Medvi story because the narrative is compelling: one founder, AI tools, $20,000, and a billion-dollar trajectory. LUKE shares the structural elements of that narrative — a three-person, AI-augmented team that simultaneously built and operates two production SaaS platforms (LUKE and Artemis) with enterprise-grade compliance, six integrated product domains, and live tenants — but with a critical difference: LUKE actually owns the technology.
Medvi proved a solo founder can build a $400M telehealth business with AI. It also proved what happens without proper compliance infrastructure — FDA warning letters, data breach reports, billing complaints, and regulatory risk that threatens the entire business. LUKE exists so the next Medvi doesn’t have to learn that lesson the hard way.
Investment thesis: Medvi validated that AI-augmented teams can build billion-dollar telehealth businesses with minimal capital. Then it demonstrated, publicly, every failure mode of doing so without real infrastructure. LUKE is the platform those businesses — and the thousands of practices chasing the same opportunity — should be running on. With real compliance, real infrastructure, and real switching costs.
Sources: The New York Times, Medvi profile (April 2026); Forbes, Inc., PYMNTS follow-up coverage (April 2026); Techdirt, “The New York Times Got Played By A Telehealth Scam And Called It The Future Of AI” (April 7, 2026); FDA Warning Letter, Medvi Health Inc. (February 20, 2026); BBB complaint filings; independent analysis via NewClaw Times, The Decoder, and Hacker News.
From Telehealth Infrastructure to Regulated Commerce Operating System
Three adjacent platform plays built on shared core infrastructure
LUKE’s architecture is not a telehealth platform. It is a regulated commerce operating system — multi-tenant infrastructure with per-tenant encryption, verification-gated commerce, AI engagement, CRM, compliance audit trails, and integrated advertising intelligence. Telehealth is the first vertical. The same core infrastructure supports any market where transactions require credential verification, compliance is non-negotiable, and customer engagement drives recurring revenue.
Three adjacent verticals share this pattern. Each can be launched with 65–80% code reuse from the existing LUKE and Artemis codebases, at a combined development investment of approximately $370K.
Thesis: 800,000+ franchise establishments across ~4,000 brands in the US. Franchisees spend $200–$500/month on 4–7 disconnected SaaS tools. No platform integrates local marketing automation, CRM, and AI engagement at mid-market pricing. Existing players split into franchisor-facing operations tools (FranConnect, Naranga — $500–$2,000+/mo per brand, no local marketing) and point solutions (Mailchimp, generic CRMs — no integration, no AI). The gap is clear: an integrated platform at the franchisee/location level combining Artemis targeting, AI engagement, and CRM.
Target: Mid-market franchise brands with 20–200 locations (~70% of all brands). One brand deal activates 20–50+ locations simultaneously — fundamentally different from LUKE’s one-at-a-time sales motion.
| Component | Price |
|---|---|
| Per-Location Platform | $199/mo |
| Franchisor Dashboard | $1,499/mo per brand |
| Artemis Targeting (opt-in) | $149/mo per location |
| AI Agent | Included (overages at $0.10/conv, $0.20/min voice) |
| Onboarding | $500/location + $5,000/brand |
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Franchise Brands | 3 | 10 | 25 | 50 | 80 |
| Active Locations | 60 | 250 | 750 | 1,600 | 2,800 |
| Location Revenue | $86K | $480K | $1.6M | $3.5M | $6.2M |
| Franchisor Fees | $29K | $120K | $360K | $720K | $1.15M |
| Artemis Revenue | $19K | $134K | $598K | $1.7M | $3.5M |
| AI Overages + Onboarding | $40K | $160K | $515K | $1.15M | $2.11M |
| Total Revenue | $174K | $894K | $3.1M | $7.1M | $13.0M |
Revenue per location: ~$4,600/yr (blended, including Artemis adoption at 30–55%). CAC per brand: $8,000–$15,000 (one deal activates 20+ locations). Effective CAC per location: $400–$750. LTV per location: ~$25,000 (5-year, 12% churn). LTV:CAC: 33–63x.
Development cost: ~$150K (6 months). 65% code reuse — swap clinical/Rx modules for location management and franchise reporting. Core multi-tenant architecture, CRM, AI, Artemis, and Stripe billing reuse directly.
Why this is the $100M play: At 10% of the mid-market (280 brands, ~10,000 locations), Artemis Ops reaches $46M ARR. Artemis advertising revenue scales with every location added — the flywheel is strongest in this vertical. TAM: $1–$2B.
Thesis: 33,000–35,000 vet practices in the US. ~25,000 independent practices have no online pharmacy. Chewy Pharmacy captures ~$1B+ in Rx revenue that should flow through practices. The pet pharmaceutical market is ~$12–$14B annually, with prescription meds at ~$8–$9B and compounded pet meds at ~$1.5–$2B (fast-growing). Only 25–30% of independent practices have any online pharmacy capability. Existing practice management platforms (IDEXX Cornerstone, eVetPractice, Shepherd) handle scheduling and charting but none combine PIMS + DTC Rx commerce + AI client engagement.
Target: Independent vet practices losing Rx revenue to Chewy. The pitch: “Stop losing $40K/month to Chewy — sell directly to your clients through your own branded storefront.” This is a pain point practices feel today, not a theoretical compliance benefit.
| Feature | Starter | Professional | Enterprise |
|---|---|---|---|
| Monthly Price | $599/mo | $1,199/mo | $2,499/mo |
| Veterinarians Included | 2 (+$50/mo each) | 5 (+$40/mo each) | Unlimited |
| AI Conversations | 500/mo | 2,000/mo | 5,000/mo |
| Transaction Fee | 1.5% on pet Rx commerce volume | ||
| Onboarding | $2,000 | $4,000 | Custom |
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Active Practices | 6 | 25 | 75 | 160 | 300 |
| Subscription ARR | $69K | $288K | $864K | $1.84M | $3.46M |
| Seat + AI Expansion | $5K | $30K | $110K | $290K | $600K |
| Transaction Fees (Rx) | $16K | $180K | $810K | $2.1M | $4.5M |
| Onboarding | $18K | $76K | $200K | $340K | $420K |
| Total Revenue | $108K | $574K | $2.0M | $4.6M | $9.0M |
ARPT: ~$30,000/yr (Professional tier with avg Rx commerce). CAC: $2,000–$4,000 (vet conferences, AVMA channels, compounding pharmacy referrals). LTV: ~$180,000 (5-year, 10% churn). LTV:CAC: 45–90x.
Development cost: ~$100K (4 months). Highest code reuse at ~80%. Swap patient → pet/owner, adjust clinical module for VCPR tracking, replace HIPAA enforcement with AMDUCA compliance, integrate with vet compounding pharmacies. Core multi-tenant, encryption, audit trails, commerce, AI, and CRM all reuse directly.
Why this works: Transaction fees ramp faster than LUKE because pet Rx is highly transactional — monthly heartworm, flea/tick, and chronic medication refills with auto-ship patterns. The compounding pharmacy channel (same partners as LUKE) provides batch referrals. The 25,000 practices without online pharmacy represent a $2–$3B addressable opportunity in Rx revenue recapture alone.
Thesis: ~7,500 compounding pharmacies in the US (~7,000 503A, ~500 503B). The compounding market is valued at $13–$15B annually, growing 5–7% per year driven by GLP-1 compounding, hormone therapy (BHRT), and veterinary compounding. Current technology is dominated by legacy systems (PK Software, pcaRx, Frameworks) that handle dispensing but provide no modern provider portal, digital ordering, or patient communication. Most pharmacies manage 30–80 clinic relationships via fax, phone, and spreadsheets.
Target: Growth-oriented 503A pharmacies doing $3–$8M annual revenue (~2,000 pharmacies). One pharmacy customer brings 30–80 connected clinic accounts, creating powerful network effects.
| Feature | Core | Growth | Enterprise (503B) |
|---|---|---|---|
| Monthly Price | $799/mo | $1,799/mo | $3,999/mo |
| Clinic Portals Included | 20 | 50 | Unlimited |
| Additional Clinics | $29/mo each | $19/mo each | Included |
| Transaction Processing | 0.5% on order volume | ||
| Compliance Reporting | Add-on ($199/mo) | Add-on ($199/mo) | Included |
| Onboarding | $5,000 | $8,000 | Custom |
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Pharmacy Customers | 4 | 12 | 30 | 55 | 90 |
| Connected Clinics | 120 | 480 | 1,500 | 3,300 | 5,850 |
| Pharmacy Subscriptions | $58K | $194K | $518K | $990K | $1.66M |
| Clinic Portal Fees | $22K | $115K | $432K | $1.07M | $2.11M |
| Transaction Processing | $48K | $288K | $900K | $1.98M | $3.78M |
| Compliance + Onboarding | $28K | $91K | $236K | $418K | $684K |
| Total Revenue | $156K | $688K | $2.1M | $4.5M | $8.2M |
Revenue per pharmacy: ~$91K/yr at Growth tier with avg clinic connections and order volume. CAC: $5,000–$10,000 (relationship-driven, trade shows PCCA/A4M). LTV: ~$546K (5-year, 7% churn — highest of all four platforms due to connected-clinic network lock-in). LTV:CAC: 55–109x.
Development cost: ~$120K (5 months). ~70% code reuse. Build pharmacy-specific workflows: formula management, BUD tracking, connected clinic portals, batch order processing. Core multi-tenant architecture, per-tenant encryption, audit trails, Stripe billing, and AI engagement all reuse directly.
Why this works: Compounding pharmacies are already a LUKE channel partner. PharmHub turns a channel into a product. The pharmacy becomes a customer AND a distribution channel for LUKE — every connected clinic is a warm lead for LUKE telehealth. FDA enforcement on 503A/503B compounders (accelerating in 2025–2026, especially around GLP-1s) drives demand for compliance automation. The connected-clinic network creates the highest switching costs of any platform in the portfolio.
| Platform | Y5 Revenue | Y5 Customers | Code Reuse | Dev Cost |
|---|---|---|---|---|
| LUKE (Telehealth) | $12.9M | 275 tenants | — | Built |
| Artemis Ops (Franchise) | $13.0M | 80 brands / 2,800 locations | 65% | $150K |
| LUKE Vet (Veterinary) | $9.0M | 300 practices | 80% | $100K |
| PharmHub (Pharmacy) | $8.2M | 90 pharmacies / 5,850 clinics | 70% | $120K |
| Combined | $43.1M | — | — | $370K |
Each platform feeds the others in ways no single-vertical competitor can replicate:
The $100M path: Any two of the four platforms hitting their Year 5 targets plus continued growth reaches $100M ARR by Year 7. The combined development investment to launch all three expansion platforms ($370K) is less than one enterprise sales hire. Each platform has independent product-market fit and independent revenue, reducing single-vertical concentration risk. The shared core infrastructure means marginal development cost per new vertical decreases with each launch.
None of these platforms should be pursued until LUKE has 5–10 paying tenants. Expanding before validation looks like distraction, not vision. The recommended sequence:
Sources: IFA Franchise Business Economic Outlook (2024–2025); AVMA Veterinary Market Statistics (2024); FDA Compounding Pharmacy Guidance (2025–2026); PitchBook franchise technology market data; PCCA industry reports.
Strategic Feasibility Assessment for Peptide & Hormone Therapy Operations
Digital health platform opportunity in Southeast Asia’s fastest-growing longevity market
The Philippines presents a convergence of three factors that make it a primary candidate for LUKE’s first international expansion: legislative tailwinds from the Universal Health Care Act forcing digital adoption across the entire health system, a fintech ecosystem where 57% of retail payments are already digital, and a rapidly growing affluent urban population spending aggressively on longevity medicine, hormone optimization, and peptide therapy — with no integrated platform serving the vertical.
The market is not theoretical. Clinics like the Longevity Medical Institute (BGC), House of Gaia, and PULSE Clinic are already operating in the peptide and hormone space, charging premium rates to an affluent demographic concentrated in Metro Manila. But the patient journey is fragmented: consultation at one clinic, blood work at a third-party lab, prescription filled at a specialty compounding pharmacy, follow-up via WhatsApp. LUKE’s architecture — clinical workflows, Rx-gated commerce, lab integration, AI engagement, and compliance audit trails — solves this exact fragmentation.
The Philippine healthcare system operates as a dual-sector model: a tax-funded public system managed by the Department of Health (DOH) and Local Government Units (LGUs), and a market-oriented private sector that now controls 53% of hospital beds. For LUKE’s premium therapy focus, the private sector is the entry point.
| Component | Public Sector | Private Sector |
|---|---|---|
| Funding | Tax revenues, PhilHealth subsidies | User fees, HMOs, Private Insurance |
| Governance | DOH (National), LGUs (Local) | Market-oriented, FDA/DOH regulated |
| Primary Care | Barangay Health Stations, RHUs | Private Clinics, Corporate Wellness |
| Facility Quality | Distributed, often under-resourced | Concentrated in Urban Centers (NCR) |
| Patient Demographics | Indigent and low-income populations | Middle/high-income, Expats |
The systemic migration of medical staff to Western nations has created a personnel vacuum that digital platforms are uniquely positioned to address through remote consultation and triage. Physicians in the private sector are on par with international counterparts, and facilities are equipped for the specialized diagnostics required for hormone optimization.
Republic Act No. 11223 (2019) is the most significant legislative shift in Philippine healthcare in decades, automatically enrolling all Filipino citizens in the National Health Insurance Program via PhilHealth. The Act mandates a transition from hospital-centric to primary-care-oriented delivery through Health Care Provider Networks (HCPNs), creating a strategic opening for telehealth platforms that integrate into these networks.
| Metric | Current Status | 2040 Target |
|---|---|---|
| Bed Density (per 1,000 pop) | 1.2 | 4.0 |
| Additional Beds Needed | — | 400,000 |
| Primary Care Physician Gap | — | 60,000 |
| Additional RHUs Needed | 3,900 existing | +2,400 |
| Healthcare Spending (% GDP) | ~0.6% on infrastructure | Sustained increase needed |
The UHC Act seeks to integrate private providers into public healthcare networks, but complex accreditation requirements have slowed adoption. LUKE can bridge this gap by offering a standardized, digitally-native interface that allows private practitioners to coordinate with the broader system while maintaining their specialized focus on high-margin longevity treatments.
The regulatory environment has transitioned from ad-hoc pandemic response to a formalized legal framework. Joint Administrative Order No. 2021-0001 institutionalized telemedicine as an integral delivery mode under the UHC Act. Non-negotiable requirements for any platform:
LUKE’s existing architecture — per-tenant AES-256-GCM authenticated encryption, hash-chained audit trails, PostgreSQL row-level security — already satisfies the core technical requirements. The Data Privacy Act of 2012 maps closely to HIPAA’s framework, making compliance adaptation straightforward rather than a ground-up rebuild.
Under Administrative Order No. 2014-0034 and FDA Circular No. 2014-025, compounding is a recognized specialty in the Philippines. Apotheca Integrative Pharmacy is the pioneer, holding licenses for both non-sterile (2014) and sterile (2016) compounding, with a focus on BHRT, thyroid medication, and weight management. This provides a clear fulfillment partner for LUKE’s Philippine operations.
| Medication Category | PH FDA Classification | Regulatory Requirement |
|---|---|---|
| High Molecular Weight Hormones | Biological Product | Abridged or Verification review for registration |
| Peptides (e.g., Semaglutide) | Prescription Drug / Biological | Valid physician prescription for dispensing |
| Compounded Formulations | Personalized Preparation | Exempt from CPR if prepared for specific patient by licensed pharmacy |
| Unregistered Supplements | Restricted / Prohibited | Public health warnings issued against online purchase |
The global peptide regulatory landscape is in flux. The US FDA’s reclassification of 19 peptides (BPC-157, CJC-1295, Ipamorelin, Thymosin Alpha-1) into “Category 2” created uncertainty, but early 2026 signals suggest ~14 may return to Category 1. Philippine pharmacies rely on USP-grade ingredients and are sensitive to these shifts. A platform that maintains real-time regulatory awareness becomes a competitive moat — physicians need a “safe harbor” for prescribing advanced therapies.
The appetite for longevity medicine in the Philippines is expanding rapidly among affluent urban demographics in Bonifacio Global City (BGC), Makati, and Ortigas. This segment is price-insensitive relative to UHC populations and focused on concierge health experiences.
The opportunity: a patient currently visits a longevity clinic in BGC, gets blood work at a third-party lab, and has a prescription filled at a specialty pharmacy — three disconnected systems. LUKE digitizes this entire patient loop from epigenetic age testing to automated peptide delivery.
Serviceable addressable market: 500–1,500 practices in the direct longevity/hormone/functional medicine vertical, expanding to 3,000–4,000 when including premium wellness, integrative medicine, and aesthetic clinics with hormone adjacency. Metro Manila concentrates 30–35% of private healthcare capacity.
LUKE’s US pricing ($799–$3,499/month) requires significant adjustment for the Philippine market. Target physicians in Metro Manila earn ₱200K–500K/month in private practice; the sweet spot for premium SaaS is 2–5% of gross revenue. The leading Philippine EMR (SeriousMD) charges ₱999–3,999/month for generic practice management — LUKE at 3–5x is defensible given the specialized vertical, Rx commerce, compounding integration, AI engagement, and compliance infrastructure.
The entire longevity and peptide market in the Philippines is cash-pay. PhilHealth and private HMOs do not cover hormone optimization, peptide therapy, BHRT, or GLP-1 for weight management. This eliminates insurance billing complexity and means physicians retain 100% of fees with no claims processing overhead.
| Component | Starter | Professional | Enterprise |
|---|---|---|---|
| Monthly Price | ₱9,999/mo (~$175) | ₱19,999/mo (~$351) | ₱39,999/mo (~$702) |
| Annual Price (15% discount) | ₱8,499/mo | ₱16,999/mo | ₱33,999/mo |
| Providers Included | 2 | 5 | Unlimited |
| Additional Providers | ₱2,999/mo each | ₱1,999/mo each | Included |
| AI Conversations | 500/mo | 2,000/mo | 5,000/mo |
| AI Overage | ₱5/conv | ₱5/conv | ₱4/conv |
| Transaction Fee | 2% on facilitated Rx commerce volume | ||
| Onboarding (one-time) | ₱50,000 | ₱100,000 | Custom |
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Active Tenants | 8 | 25 | 60 | 110 | 180 |
| Subscription ARR | ₱1.4M | ₱5.1M | ₱13.7M | ₱27.7M | ₱47.5M |
| Seat + AI Expansion | ₱120K | ₱600K | ₱2.2M | ₱5.0M | ₱9.4M |
| Transaction Fees (2% Rx) | ₱580K | ₱3.6M | ₱12.6M | ₱28.4M | ₱54.0M |
| Onboarding | ₱600K | ₱1.3M | ₱2.6M | ₱3.8M | ₱5.3M |
| Total Revenue (PHP) | ₱2.7M | ₱10.6M | ₱31.1M | ₱64.9M | ₱116.2M |
| Total Revenue (USD) | $47K | $186K | $546K | $1.14M | $2.04M |
Blended ARPU: ₱15,000/mo (Year 1) rising to ₱22,000/mo (Year 5) as tenant mix shifts toward Professional and Enterprise tiers. Transaction fee per tenant: ~₱6,000–25,000/mo scaling with patient panels (avg 30–50 peptide patients at ₱15,000/mo treatment cost). Monthly operating burn: ₱900K ($15.8K) for a 5–8 person Philippine team (developers, support, sales, compliance). Breakeven: ~50 tenants (mid-Year 2).
Technical feasibility is supported by unprecedented digital adoption: 97.5 million Filipinos online (83.8% penetration), mobile connections at 122% of population. The BSP Digital Payments Transformation Roadmap has driven digital transactions to 57.4% of retail payment volume and 59.0% of value by 2024.
| Payment Provider | User Base | Transaction Fees | Key Features |
|---|---|---|---|
| GCash | 76 Million | 2.0–2.5% (cards) | Dominant P2M and QR Ph network |
| Maya | 47 Million | 2.5% (cards) | Strong banking integration, high-yield savings |
| PayMongo | — | 3.5% + ₱15 | Developer-friendly, broad card support |
| HitPay | — | 3% + ₱15 (cards) / 1% (QR Ph) | Low blended rates, no monthly fees |
| Xendit | — | 3.2% + ₱10 | Consistent APIs across Southeast Asia |
QR Ph, the national QR code standard, has reduced merchant barriers with fees as low as 1.0% or a flat ₱20. For LUKE’s high-ticket recurring subscriptions, integration with GCash and Maya is critical — both have evolved into super-apps offering credit and insurance that could finance expensive regenerative treatments. Cross-border fees (~1% for non-Philippine cards) and payout fees must be factored into unit economics.
The Philippine telehealth market is dominated by generalist platforms backed by large corporate ecosystems. None serve the specialized peptide and hormone vertical.
| Platform | Type | Key Strengths | LUKE Differentiation |
|---|---|---|---|
| KonsultaMD | Telehealth | ~7M users, 24/7, Globe Telecom-backed | High-volume, low-acuity — no Rx commerce |
| mWell | Health Super-App | Metro Pacific hospital network | Generalist; no compounding integration |
| SeriousMD | EMR / B2B | Standard for private clinic management | No e-commerce, no lab integration, no AI |
| Hi-Precision | Diagnostics | Largest lab network, digital results | Lab-only; potential integration partner |
| Doctor Anywhere | Telehealth | Regional (SEA), bundled with HMOs | Generalist; no specialization in longevity |
The most relevant competitor is SeriousMD, the “OS” for thousands of Filipino doctors, offering EMR, billing, and patient discovery. Its strength: offline functionality essential for hospitals with intermittent Wi-Fi, plus PhilHealth billing localization. However, SeriousMD offers no Rx-gated commerce, no compounding pharmacy integration, no AI patient engagement, and no lab ordering workflow — the exact capabilities that define LUKE’s value proposition.
The market is moving toward “Super-app Health Ecosystems” where the platform controls the entire journey from diagnosis to delivery. LUKE enters this race with the specialized infrastructure already built.
Foreign healthtech firms register as a Domestic Corporation through the SEC’s eSPARC platform. 100% foreign ownership is permitted for IT/SaaS companies, subject to a $200,000 minimum capital threshold unless classified as export-oriented or high-tech innovation under the Innovation Act.
Three converging forces create a “perfect storm” for LUKE in the Philippines:
1. The UHC Leapfrog: The government’s push for digital integration under the UHC Act is forcing system-wide EMR and telemedicine adoption. A specialized platform that integrates with national standards while offering high-end, out-of-pocket services can leapfrog the public system’s infrastructure gaps.
2. The Cashless Shift: The BSP’s success in digitalizing 60% of retail payments means a remote, subscription-based model for hormone therapy is now culturally and technically feasible for millions of Filipinos.
3. The Specialization Void: While generalist telehealth platforms fight a “race to the bottom” on consultation fees, the high-margin market for longevity medicine, performance optimization, and BHRT is fragmented and underserved. No platform integrates the full clinical workflow.
The “Physician-Patient Relationship” (PPR) is the legal heart of every transaction. Under DOH guidelines, the physician assumes full liability for remote diagnosis. LUKE’s platform must include robust clinical governance:
LUKE should not enter the Philippines as a standalone clinic, but as an Integrator Platform — the digital glue connecting PRC-licensed longevity physicians, ISO-accredited labs (Hi-Precision), and FDA-licensed compounding pharmacies (Apotheca) into a single, auditable workflow.
| Integration Layer | Philippine Partner | LUKE Module |
|---|---|---|
| Clinical Consultation | PRC-licensed longevity physicians | Telehealth + SOAP notes + e-prescriptions |
| Diagnostics | Hi-Precision, Quest Philippines | Lab ordering + results integration |
| Rx Fulfillment | Apotheca Integrative Pharmacy | Rx-gated commerce + compounding workflow |
| Payments | GCash, Maya, PayMongo | Subscription billing + transaction processing |
| Patient Engagement | — | AI agent + CRM + automated follow-ups |
| Compliance | NPC, DOH, FDA-PH | Per-tenant encryption + audit trails + PNDF |
This model bypasses the need for expensive physical infrastructure while capitalizing on the rapid digitalization of the Filipino consumer. Each integration partner becomes a channel: Hi-Precision labs refer patients needing ongoing monitoring, Apotheca refers physicians needing a digital workflow, and physicians refer patients needing accessible, compliant care.
Cross-portfolio synergy: The Philippine expansion strengthens the broader LUKE ecosystem. Compounding pharmacy relationships in the Philippines feed PharmHub’s international roadmap. AI engagement patterns from a new demographic improve the model for all tenants. And the “Integrator” playbook — once proven in Metro Manila — becomes the template for expansion across Southeast Asia: Bangkok, Singapore, and Kuala Lumpur share similar demographics, regulatory structures, and digital payment maturity.
Sources: Philippine Statistics Authority (2024–2025); DOH Philippine Health Facility Development Plan 2020–2040; BSP Digital Payments Transformation Roadmap (2024); Republic Act No. 11223 (UHC Act); FDA Circular No. 2020-037; Joint Administrative Order No. 2021-0001; National Privacy Commission guidelines; PhilHealth eClaims documentation; IFA, PCCA industry reports.
Strategic Feasibility Assessment for Peptide & Hormone Therapy Operations
Longevity platform opportunity in the world’s most advanced aging society
Japan presents the strongest structural case for LUKE’s international expansion. The world’s most aged population (29%+ over 65) is driving explosive demand for longevity medicine, hormone optimization, and regenerative treatments — yet universal health insurance explicitly excludes these therapies. This creates a rapidly expanding jiyū shinryō (self-pay medicine) sector where private clinics charge 100% out-of-pocket for premium treatments with no platform purpose-built for the vertical.
Japan’s 104,894 private clinics — 94.9% physician-owned ambulatory practices — represent a massive base of autonomous “owner-physicians” (kaigyo-i) with both the income (¥40M–60M+/year) and decision-making authority to adopt specialized SaaS. Clinic owners earn 7.3x the national average wage, the highest physician-to-population income ratio among major developed nations. The “medical diet” boom (GLP-1 off-label prescribing), men’s health clinics, and beauty clinics expanding into regenerative medicine are all converging on the exact workflow LUKE was built to serve.
Japan’s universal coverage system, in place since 1961, ensures every resident has access to medical services at nationally standardized prices. The system splits into employer-based insurance (Shakai Hoken) and National Health Insurance (Kokumin Kenko Hoken), with essentially identical benefit packages. Patient copayments are structured by age:
| Age Group | Copayment Rate | Exception |
|---|---|---|
| Children (under 6) | 20% | — |
| General (6–69) | 30% | — |
| Elderly (70–74) | 20% | 30% for high-income earners |
| Elderly (75+) | 10% | 30% for high-income earners |
This 70–90% government coverage creates a psychological price ceiling for standard care. Patients are accustomed to low out-of-pocket costs, which means LUKE’s self-pay model must articulate a clear “premium” value proposition that justifies 100% patient responsibility. The structural opportunity: NHI covers “sickness” but explicitly excludes wellness, anti-aging, and preventive longevity treatments — creating a vacuum that jiyū shinryō clinics are filling at premium price points.
Japan’s “free access” system allows patients to visit any specialist without referral, which encourages patients to seek out boutique longevity clinics but also increases the need for CRM and patient engagement tools to prevent “clinic-hopping” — exactly what LUKE provides.
Telemedicine (onrain shinryō) reached permanent legal status in January 2022 when the MHLW revised guidelines to permit first-visit online consultations under specific conditions. The 2024 revisions further clarified cross-border rules and implementation principles.
NHI reimbursement for telemedicine is now nearly identical to in-person rates (post-2022 revision), removing the financial disincentive for clinics. While LUKE primarily targets self-pay clinics, NHI claim processing capability increases platform stickiness for hybrid practices.
The PMDA regulates pharmaceuticals with rigor, but Japan’s jiyū shinryō framework grants physicians significant leeway to prescribe drugs off-label or use unapproved drugs under full clinical responsibility. This is the primary legal mechanism through which BHRT and peptide therapies are delivered in the private sector.
| Treatment | PMDA Status | Commercial Context |
|---|---|---|
| Testosterone (TRT) | Approved (injections/gels) | High demand in Men’s Health clinics |
| Estrogen / Progesterone | Approved for menopause | Central to BHRT self-pay clinics |
| GLP-1 Agonists | Approved for diabetes | Exploding off-label “medical diet” market |
| Ipamorelin / CJC-1295 | Not PMDA-approved | Prescribed in longevity clinics via import |
| BPC-157 / Thymosin | Not PMDA-approved | Used in regenerative clinics; limited data |
| NMN Drips / IV Therapy | Generally classified as “Health” | Popular in beauty and longevity clinics |
Unapproved peptides are handled through the yakkan shōmei (import certificate) process, allowing physicians to import substances for specific patients. Patient costs in self-pay longevity clinics are significantly higher than NHI-covered care:
These price points demonstrate high willingness-to-pay among LUKE’s target demographic and validate that platform subscription costs represent a small fraction of per-patient treatment revenue.
Japan’s anti-aging market is one of the most developed globally, driven by the cultural priority of “healthy longevity” (kenkō jumyō). The anti-aging products market was valued at $2.92B in 2024, growing at 7.6–8.9% CAGR. Including medical services, the market reaches an estimated $7.4B in 2025.
| Market Segment | Size (2024/25) | CAGR | Target Demographics |
|---|---|---|---|
| Anti-Aging Products | $2.92B | 7.6–8.9% | Gen X, Baby Boomers |
| Anti-Aging Services | $7.4B | 5.23% | High-NW urban residents |
| Medical Tourism | $1.24B | 28.3% | Affluent Asian tourists (China, Taiwan, SEA) |
| EMR / Digital Health | $2.15B | 5.41% | Private clinics |
Japanese clinic owners (kaigyo-i) earn dramatically more than hospital-employed physicians, and possess both the capital and autonomy to adopt specialized SaaS platforms.
| Physician Type | Annual Income (JPY) | Annual Income (USD) | Context |
|---|---|---|---|
| Entry-Level Physician | ¥14.1M | ~$91K | Hospital-based, 1–3 years |
| Average Physician | ¥20.9M | ~$135K | National average, all ages |
| Senior Physician | ¥23.6M | ~$152K | Hospital-based, 8+ years |
| Clinic Owner (Urban) | ¥40M–60M+ | $260K–$390K+ | Self-employed owner-physician |
Current SaaS spending among Japanese clinics is modest. Cloud EMRs like M3 DigiKar and CLINICScloud are priced for mass-market adoption. Telemedicine platforms like curon and SOKUYAKU use a “¥0 monthly” model, monetizing via 3.6–4.0% transaction fees and patient-side usage fees (~¥330). YaDoc charges ¥33,000/month (~$215) for chronic disease management. For LUKE’s “practice-in-a-box” — CRM, AI engagement, Rx-commerce, and compliance — the premium tier anchors significantly higher.
Japan is a high-income market where physician purchasing power supports pricing at 50–65% of US rates — dramatically different from the 77–80% reduction required in the Philippines. Clinic owners generating ¥100M+ in annual revenue can absorb ¥80K–200K/month for infrastructure that directly drives high-margin self-pay revenue.
| Component | Basic | Professional | Enterprise |
|---|---|---|---|
| Monthly Price | ¥59,000/mo (~$385) | ¥99,000/mo (~$645) | ¥199,000/mo (~$1,300) |
| Annual Price (15% discount) | ¥50,150/mo | ¥84,150/mo | ¥169,150/mo |
| Providers Included | 2 | 5 | Unlimited |
| Additional Providers | ¥9,900/mo each | ¥6,600/mo each | Included |
| AI Conversations | 500/mo | 2,000/mo | 5,000/mo |
| AI Overage | ¥15/conv | ¥15/conv | ¥12/conv |
| Transaction Fee | 3% on facilitated Rx commerce volume | ||
| Onboarding (one-time) | ¥200,000 | ¥400,000 | Custom |
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Active Tenants | 20 | 75 | 200 | 500 | 1,000 |
| Blended ARPU (monthly) | ¥95K | ¥100K | ¥110K | ¥120K | ¥130K |
| Subscription ARR | ¥22.8M | ¥90M | ¥264M | ¥720M | ¥1.56B |
| Rx Transaction Fees (3%) | ¥4M | ¥15M | ¥60M | ¥180M | ¥400M |
| Total Revenue (JPY) | ¥26.8M | ¥105M | ¥324M | ¥900M | ¥1.96B |
| Total Revenue (USD) | $174K | $682K | $2.1M | $5.8M | $12.7M |
CAC: ¥400,000 (~$2,600) — higher than US due to relationship-driven, localized sales cycles. LTV (3-year): ¥4,320,000 (~$28,000). LTV:CAC: 10.8x. Monthly OPEX (Tokyo team of 4): ¥5.5M (~$36K) covering salaries, office (Minato-ku), and compliance. Breakeven: 45 tenants (mid-Year 2).
Internet penetration is near-universal and smartphone adoption is high among LUKE’s target demographic (affluent urban professionals aged 30–60). Japan’s cashless transformation is advancing, with QR-code payments like PayPay (60M+ users) and LINE Pay increasingly ubiquitous alongside traditional credit cards.
| Payment Provider | Fee Structure | Key Features |
|---|---|---|
| Stripe Japan | ~3.6% | Global standard, easy recurring billing, familiar API |
| GMO Payment Gateway | 3–4% range | Furikomi (bank transfer) and konbini (convenience store) support |
| PAY.JP | 3.0–3.6% | Popular among domestic Japanese startups |
| Square Japan | 3.25–3.95% | Strong in-clinic POS integration |
Critical operational note: Many Japanese clinics prefer a “Monthly Invoice → Bank Transfer” (furikomi) workflow over automated credit card charges. LUKE’s billing engine must offer a localized invoice/manual payment option alongside automated processing to reduce friction during the sales cycle.
| Platform | Model | Monthly Cost | LUKE Differentiation |
|---|---|---|---|
| CLINICScloud (Medley) | Cloud EMR + telehealth | Tiered subscription | Generalist; no Rx commerce, no longevity protocols |
| curon (MICIN) | Telehealth | ¥0 (3.6–4% transaction fee) | Lightweight teleconsult only; 7,000+ clinics |
| LINE Doctor | Patient marketplace | ¥0 | Convenience-driven; no clinical workflows |
| YaDoc | Chronic disease mgmt | ¥33,000 | Disease monitoring only; no e-commerce or AI |
| ORCA | NHI claims / EMR | Open source | Legacy; NHI-only, no self-pay workflows |
The gap: No platform in Japan is purpose-built for the high-ticket longevity and regenerative medicine vertical. Existing tools handle 30-patient-per-hour GP flows. LUKE’s value is in “low-volume, high-value” care where patient retention across multi-month peptide cycles, concierge-level engagement, and seamless Rx e-commerce are the primary revenue drivers.
| Establishment Cost | Godo Kaisha (GK) | Kabushiki Kaisha (KK) |
|---|---|---|
| Registration Tax | ¥60,000 | ¥150,000+ |
| Notarization Fee | ¥0 | ~¥50,000 |
| Total Setup (w/ professional help) | ~¥150,000 | ~¥350,000 |
| Timeline | 1–2 weeks | 2–4 weeks |
Recommended: Godo Kaisha (GK) — Japan’s LLC equivalent. Lower cost, faster setup, and eligible for “check-the-box” pass-through taxation under US law. KK carries more prestige for recruiting senior medical advisors but adds complexity.
1. The Demographic Imperative: 29%+ of Japan’s population is over 65 — creating unprecedented demand for longevity medicine that NHI explicitly excludes. The jiyū shinryō sector is the fastest-growing segment in Japanese healthcare, and no platform serves it.
2. The Physician-Entrepreneur: Japan’s 104,894 clinic owners have the highest physician-to-wage income ratio in the developed world and full autonomy to adopt SaaS. They are not hospital administrators requiring procurement committees — they are independent decision-makers.
3. The Revenue Multiple: Japan’s higher treatment price points (¥48K–158K/month per patient) and 3% transaction fees mean LUKE generates 3–6x more per-tenant revenue than in the Philippines. At 1,000 tenants, Japan alone reaches ¥1.96B ($12.7M) — comparable to LUKE’s core US Year 5 projection of $12.9M.
| Market Layer | Clinics | Description |
|---|---|---|
| TAM | 104,894 | All private clinics in Japan |
| SAM | 15,000 | Internal medicine, beauty, and dermatology clinics offering jiyū shinryō |
| SOM | 3,000 | High-end clinics in Tokyo, Osaka, and Nagoya specializing in longevity and BHRT |
Cross-portfolio synergy: Japan’s medical tourism boom (28.3% CAGR) positions LUKE-powered clinics as destinations for affluent patients across Asia. A clinic running LUKE in Tokyo can serve patients from China, Taiwan, and Southeast Asia with the same compliance infrastructure. The “Integrator” playbook proven in Metro Manila extends naturally to Tokyo, and compounding pharmacy relationships in both markets strengthen PharmHub’s international roadmap.
Sources: MHLW Medical Facility Survey (2023); PMDA pharmaceutical classification data; MHLW “Principles for the Appropriate Implementation of Online Medical Services” (2022, revised 2024); Japan Medical Association telemedicine guidelines; National e-prescription adoption statistics (Feb 2025); Act on the Protection of Personal Information (APPI); Statista Japan healthcare market data; Ken Research anti-aging market reports; JETRO foreign entity establishment guidelines.
Strategic Feasibility Assessment for Peptide & Hormone Therapy Operations
High-income, English-speaking market with established compounding infrastructure and exploding GLP-1 demand
Australia combines the highest-value characteristics of every market LUKE has assessed: physician incomes comparable to the US (A$200K–600K+), an English-speaking population requiring minimal localization, a well-established compounding pharmacy industry (A$166M, 6.2% CAGR), and a GLP-1 weight-loss market that has grown 10-fold in five years with 47.8% of prescriptions filled privately. The regulatory environment is stricter than the US — particularly around Schedule 4 advertising restrictions and AHPRA’s anti-asynchronous prescribing stance — but LUKE’s compliance-first architecture (real-time consultations, Rx-gated checkout, audit trails) is purpose-built for exactly this kind of regulatory framework.
The structural tailwind is unmistakable: out-of-pocket medical expenses hit a historic A$1.37B in 2024, up from A$779M five years ago. The 15.4% annual rise in OOP costs — the highest on record — reflects a “two-speed” healthcare economy where elective longevity treatments are increasingly self-funded. Over 80% of practice owners are concerned about their clinic’s financial viability under the traditional Medicare model. LUKE offers these physicians a transition to high-margin, self-pay longevity medicine with the platform infrastructure to make it work.
Australia’s hybrid system combines universal Medicare coverage with a significant private sector. Medicare provides free or subsidized access through the Medicare Benefits Schedule (MBS), covering approximately 70–90% of standard care costs. The patient copayment for most services under 70 is 30% of the scheduled fee.
| Funding Source | Share | Role in Longevity Market |
|---|---|---|
| Federal Government | 41% | Controls MBS/PBS; primary regulator via TGA |
| State/Territory Governments | 27% | Manage public hospitals |
| Individuals (Out-of-Pocket) | 17% | Primary driver for LUKE — elective therapies |
| Private Health Insurers | 9% | Minimal coverage for BHRT/Peptides |
| Non-Government Organisations | 6% | Limited relevance |
Private health insurance (PHI) covers 45.2% of the population but now pays only 66.7% of total hospital/medical costs after Medicare — down from 75.7% five years ago. Over 400,000 Australians have downgraded cover. Critically for LUKE, PHI excludes virtually all longevity treatments: BHRT, peptide therapy, GLP-1 for weight management, IV infusions, and anti-aging protocols are entirely out-of-pocket. The PBS subsidizes GLP-1 agonists only for patients with poorly controlled Type 2 Diabetes meeting strict criteria; weight-loss patients pay full private prescription prices of A$250–700/month.
Australian telehealth regulation has converged on a safety-oriented stance designed to curb “unethical business models.” AHPRA’s October 2025 update mandates that telehealth must adhere to the same professional standards as face-to-face consultations. The individual practitioner — not the platform — bears sole responsibility for care quality.
AHPRA recorded 586 telehealth-related notifications in 2024–25, reflecting increased scrutiny of single-treatment telehealth clinics. LUKE’s compliance-first design — real-time consultations, prescription audit trails, and gated e-commerce — positions it as the antidote to the regulatory concerns driving these notifications.
The TGA operates a more restrictive framework than the FDA for peptides and unapproved hormones. Most longevity substances are Schedule 4 (Prescription Only) but many are not listed on the Australian Register of Therapeutic Goods (ARTG), making them “unapproved therapeutic goods” accessible only via the Special Access Scheme (SAS), Authorized Prescriber pathway, or as personalized compounded preparations.
| Substance | TGA Schedule | Regulatory Stance |
|---|---|---|
| GLP-1 RAs (Semaglutide) | Schedule 4 | Prescription-only; strict ban on direct-to-consumer advertising |
| BHRT (Testosterone) | Schedule 4 | Requires risk assessment and individual script; high scrutiny |
| Peptides (BPC-157) | Schedule 4 / Prohibited | Many “unapproved”; TGA has warned against online “backyard” labs |
| Melanotan II | Schedule 4 / Dangerous | Linked to serious health issues; supply without script is illegal |
| Retatrutide | Experimental | Clinical trials only; no legal sale for human use outside trials |
Critical advertising restriction: It is an offense to advertise Schedule 4 medicines directly to the public in Australia, including stating prices or using brand names like “Ozempic” in marketing. The TGA has issued infringement notices to telehealth operators for unlawful weight-loss advertising and requested removal of over 13,700 unlawful digital ads in early 2026. For LUKE’s Rx-gated e-commerce, pricing and medication names can only be visible within a secure portal after a clinician establishes medical need — exactly how the platform is designed.
Australia’s compounding pharmacy industry is well-established and directly analogous to the US model. Key players include Oxford Compounding, National Custom Compounding, Key Compounding Pharmacy, and Green Dispensary Compounding, all operating under PCCA standards with sterile laboratory environments. The market is valued at A$166.3M, growing at 6.2% CAGR to A$252.9M by 2030.
Australia’s longevity market is in hyper-growth, driven by a health-conscious population and strong fitness culture. The GLP-1 market has grown 10-fold between 2020–2025, with 47.8% of prescriptions filled privately — approximately 240,000 Australians paying out-of-pocket every month. The broader GLP-1 market is projected to grow from A$4B to A$36B over the next three years.
| Market Segment | 2025 Value | Forecast | CAGR |
|---|---|---|---|
| Global Anti-Aging Products | $55.66B USD | $107.61B (2033) | 8.9% |
| Australia Anti-Aging Supplements | $135.5M USD | $267.6M (2033) | 9.1% |
| Australia Compounding Pharmacies | A$166.3M | A$252.9M (2030) | 6.2% |
| Global Longevity Drugs | $9.06B USD (2026) | $25.09B (2035) | 10.5% |
Average monthly patient spend for comprehensive weight management is approximately A$450, with maintenance plans from A$96/month. For BHRT and peptide protocols, monthly treatment costs range from A$300 to A$800+, representing high per-patient revenue for practices on the LUKE platform.
Australian physicians, particularly practice owners and specialists, represent a high-income demographic. Most GPs operate as independent contractors retaining 65–70% of billings, making them autonomous decision-makers for SaaS adoption.
| Career Stage / Specialty | Annual Income (AUD) | Annual Income (USD) | Billing Model |
|---|---|---|---|
| Intern (PGY1) | A$75K–85K | ~$49K–55K | Salaried (public hospital) |
| GP Registrar | A$85K–130K | ~$55K–85K | Salary or % billings |
| Fellowed GP (Metro) | A$200K–350K+ | ~$130K–228K | Independent contractor |
| Rural / Remote GP | A$250K–500K+ | ~$163K–325K | High demand + rural incentives |
| Surgeon | A$472K (avg taxable) | ~$307K | Private / hospital hybrid |
| Dermatologist | A$450K–600K | ~$293K–390K | High self-pay aesthetics focus |
Current healthcare SaaS spending is modest: Cliniko starts at A$45/month for solo practitioners (A$395 for large groups), Zedmed at A$129/month, Coviu at A$35/month for pure telehealth. No existing platform combines CRM, Rx-gated commerce, AI engagement, and longevity-specific workflows. Over 80% of practice owners are concerned about financial viability under the bulk-billing Medicare model (A$39.10 per consult), creating strong motivation to transition to self-pay longevity medicine with the right platform infrastructure.
Australia’s high physician income and English-language compatibility support pricing at 53–72% of US rates — between Japan’s premium positioning and the Philippines’ aggressive localization discount. The established compounding pharmacy industry and strong GLP-1 demand mean transaction fee revenue scales immediately.
| Component | Starter | Professional | Enterprise |
|---|---|---|---|
| Monthly Price | A$649/mo (~$420 USD) | A$1,199/mo (~$780 USD) | A$2,499/mo (~$1,625 USD) |
| Annual Price (15% discount) | A$549/mo | A$1,019/mo | A$2,124/mo |
| Providers Included | 2 | 5 | Unlimited |
| Additional Providers | A$99/mo each | A$69/mo each | Included |
| AI Conversations | 500/mo | 2,000/mo | 5,000/mo |
| AI Overage | A$0.15/conv | A$0.15/conv | A$0.12/conv |
| Transaction Fee | 2.5% on facilitated Rx commerce volume | ||
| Onboarding (one-time) | A$3,500 | A$7,000 | Custom |
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Active Tenants | 12 | 40 | 100 | 200 | 350 |
| Blended ARPU (monthly) | A$1,000 | A$1,100 | A$1,200 | A$1,300 | A$1,400 |
| Subscription ARR | A$144K | A$528K | A$1.44M | A$3.12M | A$5.88M |
| Seat + AI Expansion | A$12K | A$60K | A$200K | A$480K | A$980K |
| Rx Transaction Fees (2.5%) | A$36K | A$200K | A$720K | A$1.8M | A$3.68M |
| Onboarding | A$72K | A$168K | A$360K | A$600K | A$900K |
| Total Revenue (AUD) | A$264K | A$956K | A$2.72M | A$6.0M | A$11.4M |
| Total Revenue (USD) | $172K | $622K | $1.77M | $3.9M | $7.4M |
CAC: A$5,000–8,000 (~$3,250–5,200 USD) — lower than Japan due to English-language sales but higher than US due to smaller market and local relationship requirements. LTV (3-year): A$50,400 (~$32,800). LTV:CAC: 6–10x. Monthly OPEX: A$85K (~$55K) for a small Australian team (Country Manager, sales, support, compliance). Breakeven: ~35 tenants (late Year 1 / early Year 2). Exchange rate: A$1 = $0.65 USD.
| Payment Provider | Fee Structure | Key Features |
|---|---|---|
| Stripe Australia | 2.9% + 30¢ (domestic) | Standard for SaaS recurring billing; +1.5% for international cards |
| Square Australia | 1.6% (in-person) / 2.2% (online) | Strong in-clinic POS integration |
| Pin Payments | 2.9% + 30¢ | Australian-built; developer-friendly |
| eWay | 2.7% + 25¢ | Long-established AU processor; BPAY support |
Australia has near-universal internet penetration, high smartphone adoption, and strong digital literacy among the target demographic. The New Payments Platform (NPP) / PayID / Osko enables near-instant bank transfers. GST (10%) applies to digital services from non-resident businesses exceeding A$75,000 in Australian sales — LUKE must register for GST early to manage compliance and reclaim credits on local operational costs.
| Competitor | Target | Price (AUD) | LUKE Differentiation |
|---|---|---|---|
| Cliniko | Allied Health | A$45–395/mo | No Rx commerce, no BHRT/peptide focus |
| Medical Director | GPs / Chronic | Custom quote | Rigid GP-centric; poor wellness/aesthetics UX |
| Zedmed | GPs / PIP | A$129/mo | Medicare billing focus; no growth features |
| Coviu | Telehealth / Allied | A$35/mo | Pure video-consult; no e-commerce or lab integration |
| Juniper / Eucalyptus | DTC Weight Loss | A$449/mo (patient) | Consumer-facing; competes with practices, not enables them |
The gap: No Australian platform combines practice management, Rx-gated e-commerce, compounding pharmacy integration, AI patient engagement, and compliance infrastructure for the longevity vertical. Juniper and Midnight Health compete against independent practices; LUKE enables those practices to compete back. Vitura Health’s A$350K acquisition of Heyday Medical Clinic signals growing appetite for integrated longevity brands — LUKE provides the “picks and shovels” for this entire emerging industry.
| Establishment Cost | Amount (AUD) | Requirement |
|---|---|---|
| ASIC Registration (Pty Ltd) | A$611 | Mandatory for local entity |
| Legal / Constitution | A$600–2,000 | Recommended for US-parented firms |
| Accounting / Tax Setup | A$300–1,500 | ABN, TFN, GST registration |
| ASIC Annual Review | A$329/yr | Required to maintain registration |
| Insurance (PI / PL) | A$1,000–2,000/yr | Mandatory for healthtech operations |
| Total First Year | A$5,000–7,000 | — |
1. The Compliance Moat: Australia’s strict TGA advertising rules and AHPRA’s anti-asynchronous stance are actively driving “unregulated” telehealth operators out of the market. LUKE’s compliance-first architecture — real-time consultations, gated pricing, audit trails — transforms regulatory pressure from a barrier into a competitive advantage.
2. The GLP-1 Tidal Wave: 240,000 Australians paying privately for GLP-1 medications every month, with the market projected to grow from A$4B to A$36B. Independent practices need infrastructure to capture this demand before DTC platforms like Juniper absorb it entirely.
3. The English-Language Advantage: Australia is LUKE’s lowest-friction international market. No UI translation, minimal localization (currency, date format, TGA drug database), compatible timezone with Asia-Pacific expansion, and established compounding pharmacy partnerships (PCCA-standard) analogous to the US model.
| Market Layer | Practices | Description |
|---|---|---|
| TAM | 104,000+ | All private clinics and specialist rooms in Australia |
| SAM | 5,000–8,000 | Private-billing GPs, integrative, dermatology, aesthetics, men’s health |
| SOM | 1,500–2,500 | High-end clinics in Sydney, Melbourne, Brisbane, Gold Coast, and Perth |
Cross-portfolio synergy: Australia’s PCCA-standard compounding pharmacies (Oxford Compounding, National Custom Compounding) directly feed PharmHub’s international roadmap. Australia also serves as the natural hub for Asia-Pacific expansion — with timezone overlap to Japan, the Philippines, and broader Southeast Asia, a LUKE Australia team provides regional support infrastructure for all APAC markets simultaneously.
Sources: Australian Institute of Health and Welfare (AIHW) 2024; AHPRA Telehealth Guidelines (October 2025); TGA regulatory guidance on SaMD and Schedule 4 advertising; Medicare Benefits Schedule (MBS); Pharmaceutical Benefits Scheme (PBS); ASIC company registration data; Statista Australia digital health reports; Australian Private Hospitals Association; PCCA Australia compounding standards; Ken Research anti-aging market projections.
Strategic Feasibility Assessment for the Self-Pay Longevity & Aesthetic Economy
World’s #1 per-capita aesthetic medicine market — model pivot from DTC Rx e-commerce to B2B clinic SaaS
South Korea is the world’s undisputed leader in per-capita aesthetic procedures (23.5 per 1,000 people — nearly 2x the US), with a self-pay aesthetic and anti-aging market valued at $2.47B in 2024, projected to reach $12.14B by 2034. The longevity and anti-aging complementary medicine market is projected at $10.5B by 2030 (26.8% CAGR). However, two hard legal barriers require a model pivot: online pharmacy sales are prohibited (one of only two OECD countries with this ban) and remote prescribing of GLP-1s and anti-obesity drugs is explicitly banned from telemedicine.
LUKE’s path into South Korea is not DTC Rx e-commerce but B2B clinic SaaS for the self-pay wellness economy: in-clinic Rx management, KakaoTalk-integrated patient engagement, treatment package management, medical tourism workflows, and analytics. No integrated B2B platform serves this vertical — Gangnam Unni (7.2M users) and Babitalk are patient-facing marketplaces; DoctorNow is a telemedicine app. LUKE would be the clinic-side operations platform, complementary to all of them.
South Korea operates a single-payer system via the National Health Insurance Service (NHIS), covering 97% of residents. The critical distinction for LUKE is between covered (급여) and non-covered (비급여) services:
| Category | Coverage | LUKE Relevance |
|---|---|---|
| Covered (급여) | 70–90% NHIS reimbursed | Not LUKE’s target — standard care |
| Non-covered (비급여) | 100% patient self-pay | LUKE’s entire addressable market |
Non-covered services (100% self-pay): Cosmetic/aesthetic procedures, anti-obesity medications (Wegovy/Mounjaro), elective hormone replacement therapy, anti-aging treatments, hair loss medications, IV therapy, stem cell/PRP treatments, advanced diagnostics. Out-of-pocket spending at 27–30% of total health expenditure is significantly above the OECD average of 18%, reflecting the massive self-pay market. 77% of Koreans carry supplementary private insurance, indicating a population accustomed to paying for health services beyond basic coverage.
Telemedicine was legalized December 2, 2025 after a 15-year legislative impasse, but with significant restrictions:
| Provision | Detail |
|---|---|
| Scope | Follow-up care nationwide; initial consults limited to patient’s region |
| Prior visit | Face-to-face record generally required |
| Facility limitation | Clinic-level (의원) only; telemedicine-only facilities prohibited |
| Volume cap | Virtual consultations capped at 30% of total visits |
| Banned from remote Rx | Anti-obesity drugs (GLP-1s), hair loss drugs, narcotics, 23 high-risk ingredients |
| Medication delivery | Prohibited — patients must pick up from physical pharmacy |
PIPA compliance: South Korea’s Personal Information Protection Act is among the world’s strictest. Health data is “sensitive information” requiring explicit consent. Medical records must be stored on Korean servers — no offshore storage permitted. Penalties reach 3% of relevant revenue or 5 years imprisonment. LUKE must deploy Korean-hosted infrastructure (AWS Seoul or NHN Cloud).
South Korea does not have a US/Australian-style compounding pharmacy industry. Pharmacy chains are banned (one pharmacist = one pharmacy). Custom peptide and hormone formulations are not available; products must be MFDS-approved manufactured pharmaceuticals.
| Treatment | MFDS Status | Self-Pay Cost (KRW) | Cost (USD) |
|---|---|---|---|
| TRT (monthly total) | Approved | ₩300K–900K | $217–$652 |
| BHRT (estradiol/progesterone) | Approved | ₩50K–120K/mo | $36–$87 |
| Wegovy (4-week pen) | Approved, NOT reimbursed | ₩220K–600K | $159–$435 |
| Mounjaro (4-week pen) | Approved, NOT reimbursed | ₩278K–369K | $201–$267 |
| NAD+ IV therapy | Available (비급여) | ₩300K–700K/session | $217–$507 |
| Glutathione IV (“Snow White”) | Available (비급여) | ₩150K–250K | $109–$181 |
| BPC-157 / Ipamorelin | Not MFDS-approved | N/A | N/A |
| Stem cell anti-aging (program) | Available | ₩12M–35M | $8,696–$25,362 |
| Premium health check (Chaum) | Available | ₩690K–13.1M | $500–$9,500 |
| Metric | Value |
|---|---|
| Cosmetic surgery/procedures (2025) | $2.90B (projected $12.14B by 2034, 17.2% CAGR) |
| Anti-aging/longevity CAM (proj. 2030) | $10.5B (26.8% CAGR) |
| Procedures per 1,000 people | 23.5 (#1 globally; US: 12–15) |
| Non-surgical share of revenue (2024) | 71.5% |
| Medical tourists (2024) | 1,170,467 from 202 countries (+93.2% YoY) |
| Medical tourism spending (2024) | KRW 7.5T (~$5.4B) total; KRW 1.4T medical |
| Health & wellness market (overall) | $113B (9th globally) |
| Category | Annual Income (KRW) | Annual Income (USD) |
|---|---|---|
| Hospital-employed (봉직의) | ₩201M | ~$146K |
| Clinic owners (개원의) — average | ₩345M | ~$250K |
| Plastic Surgery (clinic owner) | ₩400–720M | $290K–$522K |
| Dermatology (clinic owner) | ₩300–600M | $217K–$435K |
| Ophthalmology (clinic owner) | ₩615M | ~$446K |
Gangnam aesthetic clinic revenue: ₩1–5B/year ($725K–$3.6M) for small-to-mid clinics, ₩5–20B ($3.6M–$14.5M) for larger multi-doctor practices, ₩20–50B+ ($14.5M+) for top-tier medical tourism clinics. Profit margins: 18–25% typical, 30–40% for premium practices. Current software spend: ₩1–3M/month ($725–$2,175) across fragmented tools (EMR + CRM + patient acquisition platforms). EMR market is 96% adopted but commoditized — the premium integration gap is LUKE’s opportunity.
Korean pricing at 62–63% of US rates — validated by physician income data showing Korean aesthetic specialist earnings at 60–75% of US equivalents. The model pivots from Rx e-commerce to in-clinic facilitation fees and treatment package booking fees.
| Component | Starter (단독의원) | Professional (전문의원) | Enterprise (프리미엄) |
|---|---|---|---|
| Monthly Price | ₩690,000 (~$500) | ₩1,490,000 (~$1,080) | ₩2,990,000 (~$2,167) |
| Providers Included | 1–2 | 3–5 | Unlimited |
| Additional Providers | ₩200,000/mo | ₩200,000/mo | Included |
| In-Clinic Rx Facilitation | 2.0% of dispensed value | ||
| Treatment Package Fee | 3.0% of package value (multi-session IV, GLP-1 programs) | ||
| Onboarding (one-time) | ₩3,000,000 | ₩3,000,000 | Custom |
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Active Tenants | 20 | 65 | 145 | 265 | 420 |
| Subscription ARR | ₩268M | ₩924M | ₩2.22B | ₩4.32B | ₩7.27B |
| Transaction Fees (2.3% blended) | ₩83M | ₩359M | ₩1.0B | ₩2.19B | ₩4.06B |
| Onboarding | ₩60M | ₩150M | ₩270M | ₩390M | ₩510M |
| Total Revenue (KRW) | ₩411M | ₩1.43B | ₩3.49B | ₩6.90B | ₩11.84B |
| Total Revenue (USD) | $298K | $1.04M | $2.53M | $5.0M | $8.58M |
Blended ARPU: ₩1.71M/mo ($1,241) Year 1, rising to ₩2.35M/mo ($1,702) by Year 5 as tier mix shifts toward Professional/Enterprise. CAC: ₩15M (~$10,870) — higher than other markets due to relationship-driven sales and 6–12 month cycles. LTV (at 5% annual churn): ₩390M (~$283K). LTV:CAC: 26:1. Monthly burn: ₩65M (~$47K) for a 5-person Seoul team. Breakeven: ~38 tenants (Month 18). Exchange rate: ₩1,380 = $1 USD.
South Korea has arguably the world’s best digital infrastructure: 97.4% internet penetration, 88% 5G smartphone penetration (#1 globally), and an effectively cashless society (93% non-cash transactions). Credit cards hold 54% of POS share, digital wallets 20%.
| Payment Provider | Users | Fee Range | Key Feature |
|---|---|---|---|
| NHN KCP | #1 domestic PG | 2.0–3.0% | Recurring billing (빌링키); dominant market share |
| Toss Payments | #2–3 | 2.0–3.0% | Best developer API; financial superapp (21M+ users) |
| KG Inicis | #2–3 | 2.0–3.2% | Established processor |
| Stripe Korea | Available Oct 2024 | ~3.9% | All local cards + Naver Pay + Kakao Pay; no local entity needed |
Key consideration: Korean law requires a 7-day full refund window for unused subscriptions and pro-rated refunds on cancellation at any time. Annual contracts with monthly billing are preferred for B2B.
| Platform | Type | Users | LUKE Differentiation |
|---|---|---|---|
| Gangnam Unni | Patient marketplace | 7.2M / 3,700 clinics | B2C acquisition — LUKE is B2B operations (complementary) |
| DoctorNow | Telemedicine app | 7.5M registered | Consumer teleconsult — no clinic-side SaaS |
| Goodoc | Healthcare marketplace | 12M+ cumulative | Booking/directory — no CRM, no Rx management |
| Ubicare (의사랑) | EMR | 15,000+ facilities | Commodity EMR (45% share) — no AI, no treatment packages |
| Babitalk | Aesthetic reviews | Major | Patient-facing reviews — no clinic operations |
The gap: No integrated B2B SaaS platform serves the self-pay longevity/aesthetic/hormone clinic vertical. Patient-facing platforms handle acquisition; commodity EMRs handle charting; nothing handles the end-to-end workflow of in-clinic Rx management, treatment package sales, KakaoTalk patient engagement, medical tourism coordination, and analytics. LUKE fills this void.
| Option | Capital Req. | Timeline | Best For |
|---|---|---|---|
| Liaison Office (연락사무소) | None | Fast | Exploration phase (Months 1–6) |
| Subsidiary (주식회사) | ₩100M (~$72.5K) | 4–6 weeks | Full market entry |
| Branch (지점) | None | 2–3 weeks | Market testing |
Recommended: Liaison office for 3–6 months of exploration, then 주식회사 subsidiary for full operations. Total first-year setup: ~$10K–$15K. Corporate tax: progressive 10–25% (effective max 27.5%). VAT: 10% on SaaS. US-Korea tax treaty reduces royalty withholding to 15%.
1. The Model Pivot: LUKE Korea is not telehealth + Rx e-commerce — it is the integrated clinic management platform for Korea’s $113B self-pay wellness economy. In-clinic Rx management, KakaoTalk patient engagement, treatment package booking, medical tourism workflows, and analytics replace the prohibited DTC model with a legal and potentially more lucrative B2B approach.
2. The Appearance Economy: Korea’s cultural emphasis on appearance (외모지상주의) creates unmatched demand. 75% of men do weekly grooming; anti-aging skincare begins at age 25; 23.5 cosmetic procedures per 1,000 people. This is not a niche — it is the mainstream consumer culture.
3. The Medical Tourism Multiplier: 1.17M international patients (2024, +93.2% YoY), spending $5.4B. LUKE-powered clinics in Gangnam serve as hubs for patients across Asia. Post-visit telemedicine follow-ups (legal under new MSA) create ongoing platform engagement and a bridge to LUKE’s other APAC markets (Japan, Philippines, Australia).
| Market Layer | Clinics | Description |
|---|---|---|
| TAM | 12,500 | Clinics in target verticals with meaningful 비급여 revenue |
| SAM | 3,675 | Urban, tech-receptive, revenue >₩1B/year |
| SOM (Year 5) | 420 | 11.4% of SAM; Gangnam-led, expanding to Busan/Daegu |
Cross-portfolio synergy: South Korea is LUKE’s third-highest-revenue international market ($8.58M Year 5), with pricing closest to US rates (62–63%) among all assessed markets. The medical tourism bridge connects Korea to Japan (37.7% of medical tourists are Japanese), the Philippines, and Australia. The B2B clinic SaaS pivot — forced by Korean regulation — may prove to be the most valuable model innovation of the international expansion, applicable to other markets where Rx e-commerce faces barriers.
Sources: NHIS Annual Report (2024); HIRA fee schedule data; Medical Service Act amendment (December 2025); MFDS pharmaceutical classifications; Personal Information Protection Act (PIPA); Korea Health Industry Development Institute (KHIDI) medical tourism statistics; MFDS Digital Medical Products Act (January 2025); KOTRA/Invest Korea foreign investment guidelines; Korean Medical Association policy documents; Gangnam Unni and DoctorNow public data; Ken Research and Mordor Intelligence market projections.